_pmid,_doi,_publicationTitle,_year,_context,_confidence,_verdict,_usageType,insertName,vectorType,vectorBackbone,promoter,insertSpecies,insertEntrezId,selectableMarker,copyNumber,gRNAshRNASequence
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,pAAV-hSyn-dLight1.2 Addgene Plasmid#: 111068 RRID: Addgene_111068 Gift on Lin Tian; produced by UC Davis Vector Core,0.95,Accept,Experimental Usage,dLight1.2,Viral,AAV,hSyn,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,pAAV-hSyn-hChR2(H134R)-EYFP Addgene Plasmid#: 26973 RRID: Addgene_26973 Gift of Karl Deisseroth,0.9,Accept,Experimental Usage,hChR2(H134R)-EYFP,Viral,AAV,hSyn,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,AAV9-Th-PI-Cre-SV40 Addgene Plasmid#: 107788 RRID: Addgene_107788 Addgene viral prep#: 107788-AAV9,0.9,Accept,Experimental Usage,Cre,Viral,AAV9,Th,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,pAAV-DJ-Ef1α-DO-eNpHR3.0-eYFP-WPRE-pA Addgene Plasmid#: 37087 RRID: Addgene_37087 Gift of Bernardo Sabatini,0.9,Accept,Experimental Usage,eNpHR3.0-eYFP,Viral,AAV-DJ,Ef1α,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,pAAV-DJ-Ef1α-DO-mCherry-WPRE-pA Addgene Plasmid#: 37119 RRID: Addgene_37119 Gift of Bernardo Sabatini,0.9,Accept,Experimental Usage,mCherry,Viral,AAV-DJ,Ef1α,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,pAAV-ihSyn1-tTA-WPRE Addgene Plasmid#: 99120 RRID: Addgene_99120,0.9,Accept,Experimental Usage,tTA,Viral,AAV,ihSyn1,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,pAAV-Th-tTA-WPRE Addgene Plasmid#: 133268 RRID: Addgene_133268,0.9,Accept,Experimental Usage,tTA,Viral,AAV,Th,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,pAAV-TRE-mRuby-WPRE Addgene Plasmid#: 99114 RRID: Addgene_99114,0.9,Accept,Experimental Usage,mRuby,Viral,AAV,TRE,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,pAAV-TRE-mTurquoise-WPRE Addgene Plasmid#: 99113 RRID: Addgene_99113,0.9,Accept,Experimental Usage,mTurquoise,Viral,AAV,TRE,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,pAAV-Th-GFP-WPRE Addgene Plasmid#: 99128 RRID: Addgene_99128,0.9,Accept,Experimental Usage,GFP,Viral,AAV,Th,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,pUCmini-iCAP-PHP.eB Addgene Plasmid#: 103005 RRID: Addgene_103005,0.9,Accept,Experimental Usage,iCAP-PHP.eB,Plasmid,pUCmini,,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,We employed the genetically encoded optical dopamine sensor dLight1 to monitor dopaminergic neurotransmission in the ventral striatum of NF1 mice,0.95,Accept,Experimental Usage,dLight1,Viral,,,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,Genomic DNA (gDNA) was extracted from blood or frozen tissue using Qiagen DNeasy Blood & Tissue kit (Qiagen Ca#69506),0.85,Accept,Experimental Usage,DNA extraction kit,Other,,,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,"subjected to exome enrichment using SureSelectXT Human All Exon version 5 (Agilent Technologies, Wilmington, DE, catalog# 5190-6210)",0.9,Accept,Experimental Usage,Human exome capture,Other,,,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,Cells were transduced with either lentiviral control shLacZ (Genome Institute at Washington University),0.9,Accept,Experimental Usage,LacZ,Viral,,,,,Control shRNA,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,"separate lentiviral shRNAs targeting Trim23 (Sigma; TRCN0000308323, TRCN0000308321, TRCN0000308320)",0.95,Accept,Experimental Usage,Trim23,Viral,,,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"were infected with sh NF1 1–3 lentiviral particles (Sigma; 39714, 39715, 39717)",0.95,Accept,Experimental Usage,shNF1,Viral,,,Human,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"DRG-NSCs were isolated from E13.5 embryo DRG/nerve roots, and were infected with Ad-CMV-Cre",0.9,Accept,Experimental Usage,Cre,Viral,,CMV,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Human sh COL1A2 and mouse sh Col1a2 lentiviral particles (TRCN0000090043; TRCN0000090045; TRCN0000335210),0.95,Accept,Experimental Usage,shCOL1A2,Viral,,,Human,,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,RNA was isolated from fresh blood leukocytes from two normal individuals using TRIzol LS Reagent (Invitrogen) according to the manufacturer's instructions.,0.85,Accept,Experimental Usage,TRIzol LS,Other,,,,,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,Total RNA (2 μg) was reverse transcribed using SuperScript II Reverse transcriptase (Invitrogen) and random hexamers (Amersham Biosciences).,0.85,Accept,Experimental Usage,SuperScript II,Other,,,,,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,The PCR products were cloned in the pCR2.1-TOPO-vector (Invitrogen) and transformed into TOP-10F' cells.,0.9,Accept,Experimental Usage,pCR2.1-TOPO,Plasmid,pCR2.1,,,,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,All transcripts with a different restriction pattern were sequenced (primer sequences available upon request) using the Thermo Sequenase fluorescent labelled primer cycle sequencing kit (Amersham Biosciences),0.85,Accept,Experimental Usage,Thermo Sequenase,Other,,,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,We targeted NF1's RASGAP GRD domain with clustered regularly interspaced short palindromic repeat (CRISPR) guides to the 21st exon,0.85,Accept,Experimental Usage,NF1 gRNA,Other,,,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"enzymatically digested with dispase grade II (1.25 U/mL, Roche, Basel, Switzerland)",0.85,Accept,Experimental Usage,dispase grade II,Other,,,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"collagenase type I (160 U/mL, Sigma, St. Louis, MO, USA)",0.85,Accept,Experimental Usage,collagenase type I,Other,,,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"Cell viability was evaluated using the Cell Counting Kit-8 (CCK8, Dojindo Laboratories, Kumamoto, Japan)",0.8,Accept,Experimental Usage,CCK8,Other,,,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,infection with adenovirus Ad5-CMV-Cre or Ad5-CMV-eGFP (2500 viral particles per cell; Vector Development Lab),0.9,Accept,Experimental Usage,Cre,Viral,Ad5,CMV,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,infection with adenovirus Ad5-CMV-Cre or Ad5-CMV-eGFP (2500 viral particles per cell; Vector Development Lab),0.9,Accept,Experimental Usage,eGFP,Viral,Ad5,CMV,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,"Entry clones were produced by PCR amplification of portions of the NF1 gene from Addgene construct 70423, which contains a codon-optimized version of human NF1 isoform 2",0.9,Accept,Experimental Usage,NF1 isoform 2,Plasmid,,,Human,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,PCR amplicons were cloned into pDonr255 and fully sequence-verified,0.85,Accept,Experimental Usage,Gateway entry vector,Plasmid,,,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Gateway LR recombination was used to generate final expression clones in baculovirus Destination vectors pDest-635 (pFastBac1 with N-terminal His 6 tag),0.85,Accept,Experimental Usage,baculovirus expression vector,Plasmid,pFastBac1,,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,pDest-636 (pFastBac1 with N-terminal His 6 -MBP tag),0.85,Accept,Experimental Usage,baculovirus expression vector,Plasmid,pFastBac1,,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,"E. coli Destination vector pDest-566 (N-terminal His6-MBP tag, Addgene catalog no. 11517)",0.85,Accept,Experimental Usage,E. coli expression vector,Plasmid,,,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,"Exome libraries were captured with an IDT exome reagent, then pooled with a WGS library for sequencing",0.85,Accept,Experimental Usage,exome capture,Other,,,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,"RNA was prepared with a TrueSeq stranded total RNA library kit, then sequenced on an Illumina HISeq4000",0.85,Accept,Experimental Usage,RNA library preparation,Other,,,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,Between 350 and 500 ng of tumor DNA were used to prepare DNA sequencing libraries using the TruSeq DNA PCR Free 350bp kit,0.85,Accept,Experimental Usage,TruSeq DNA PCR Free 350bp,Other,,,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,DNA extraction from FFPE tissue samples was performed using the Covaris truXTRAC FFPE DNA kit with the E220 Evolution-focused ultrasonicator system,0.85,Accept,Experimental Usage,truXTRAC FFPE DNA,Other,,,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,"Exome libraries were prepared using the Roche Kapa HyperPlus kit, captured using the HyperExome kit Roche",0.85,Accept,Experimental Usage,Kapa HyperPlus,Other,,,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,Tumor DNA derived from fresh-frozen tumors and paired normal nerve samples was used for whole-genome DNA methylation array profiling using the HumanMethylationEPIC beadchip platform,0.85,Accept,Experimental Usage,HumanMethylationEPIC,Other,,,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,350 ng of DNA were bisulfite converted using the Zymo EZ DNA methylation Gold kit (Zymo Research Corp.),0.85,Accept,Experimental Usage,EZ DNA methylation Gold,Other,,,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,"total RNA was extracted from VS and control nerve samples using the Trizol reagent (Gibco Invitrogen, Carlsbad, CA)",0.85,Accept,Experimental Usage,RNA extraction reagent,Other,,,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,"mRNA was selected by running total RNA over oligo-dT columns (Invitrogen, Carlsbad, CA)",0.8,Accept,Experimental Usage,oligo-dT,Other,,,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,"mRNA (5 μg per 50 μL sample) was reverse transcribed using the Gene AMP kit (Perkin-Elmer; Waltham, MA)",0.85,Accept,Experimental Usage,reverse transcription kit,Other,,,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,"Taqman Universal PCR Master Mix (2× buffer containing polymerase; Applied Biosystems, Foster City, CA)",0.85,Accept,Experimental Usage,PCR master mix,Other,,,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,"20× solution of primers and fluorophor-labeled probe (Taqman Gene Expression Assays; Applied Biosystems, Foster City, CA)",0.9,Accept,Experimental Usage,gene expression assay,Other,,,,,,,
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,"Cell viability results showed that three agents (GSK2126458, Panobinostat, CUDC-907) had the greatest activity across schwannoma and meningioma cell systems",0.85,Accept,Experimental Usage,GSK2126458,,,,,,,,
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,"Cell viability results showed that three agents (GSK2126458, Panobinostat, CUDC-907) had the greatest activity across schwannoma and meningioma cell systems",0.85,Accept,Experimental Usage,Panobinostat,,,,,,,,
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,"Cell viability results showed that three agents (GSK2126458, Panobinostat, CUDC-907) had the greatest activity across schwannoma and meningioma cell systems",0.85,Accept,Experimental Usage,CUDC-907,,,,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,"NF2 −/− cells should be transduced before use so they express the GLuc reporter gene, which is a secreted reporter that can be detected in the blood of tumor-bearing animals.",0.85,Accept,Experimental Usage,GLuc,Viral,,,Other,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,"GLuc vector and assay kits are commercially available from various biotech companies, such as Thermo Fisher Scientific (cat. no. 16146) and New England BioLabs (cat. no. N8084S).",0.85,Accept,Experimental Usage,GLuc,Viral,,,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,"GLuc vector and assay kits are commercially available from various biotech companies, such as Thermo Fisher Scientific (cat. no. 16146) and New England BioLabs (cat. no. N8084S).",0.85,Accept,Experimental Usage,GLuc,Viral,,,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"We infected p53−/−; Myc; Cas9 hepatocytes with the mGeCKOa lentiviral library of 67,000 single-guide RNAs (sgRNAs), targeting 20,611 mouse genes",0.9,Accept,Experimental Usage,mGeCKOa sgRNA library,Viral,,,Mouse,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,sgRNA oligos (IDT) were annealed and cloned into the pX330 vector (addgene 42230),0.85,Accept,Experimental Usage,Cas9/sgRNA,Plasmid,pX330,,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,sgRNA oligos (IDT) were annealed and cloned into the pX330 vector (addgene 42230) or lentiV2 (addgene 52961),0.85,Accept,Experimental Usage,sgRNA,Viral,lentiV2,,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"pX330.sgNf1 (20 μg), pT3-EF1α-Myc (5 μg), and CMV-SB10 transposase (1 μg) plasmids were delivered",0.85,Accept,Experimental Usage,Myc,Plasmid,pT3,EF1α,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"pX330.sgNf1 (20 μg), pT3-EF1α-Myc (5 μg), and CMV-SB10 transposase (1 μg) plasmids were delivered",0.85,Accept,Experimental Usage,SB10 transposase,Plasmid,,CMV,,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,Transgenes expressing the indicated NF2 proteins were cloned with N-terminal Flag epitope tags in the pUASt transformation vector.,0.85,Accept,Experimental Usage,NF2,Plasmid,pUASt,,Human,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,ectopic expression of the NF2 isoforms under the control of the apterous-Gal4 driver,0.85,Accept,Experimental Usage,apterous-Gal4,Other,,,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,"...sonicated for five cycles of 30 s on, 30 s off in 50 µL of 100 mM triethylammonium bicarbonate buffer supplemented with Complete Mini protease inhibitors (Roche, Basel, Switzerland)...",0.85,Accept,Experimental Usage,Complete Mini protease inhibitors,Other,,,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,"...After acidification with phosphoric acid and addition of the S-Trap binding buffer, the samples were applied to S-Trap micro spin columns (ProtiFi, Farmingdale, NY, USA)...",0.85,Accept,Experimental Usage,S-Trap micro spin columns,Other,,,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,...and detection with the UltraView Universal DAB detection kit (Roche)...,0.85,Accept,Experimental Usage,UltraView Universal DAB detection kit,Other,,,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,"...The labeling was carried out using the peroxidase-based Dako EnVision kit (Agilent Dako, Santa Clara, CA, USA)...",0.85,Accept,Experimental Usage,Dako EnVision kit,Other,,,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,"CD3+ T cells were purified from the lymph nodes using pan-T-cell isolation kit (Miltenyi Biotec, Auburn, CA)",0.8,Accept,Experimental Usage,pan-T-cell isolation,,,,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,Live cells were isolated from dead cells by staining with 7-aminoactinomycin D (Biolegend; 420403; 1:100),0.8,Accept,Experimental Usage,7-aminoactinomycin D,,,,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,"the Vecta Stain Elite ABC kit (Vectorlabs, PK-6100) was used according to the manufacturer's protocol",0.8,Accept,Experimental Usage,Vecta Stain Elite ABC,,,,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,"RNA was isolated from the knee cartilage...using peqGOLD TriFast (PeqLab Biotechnologie GmbH, Erlangen, Germany)",0.8,Accept,Experimental Usage,RNA extraction reagent,Other,,,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,"cDNA was synthesized from 1 μg of total RNA with MuLV Reverse Transcriptase (Applied Biosystems, Carlsbad, CA, USA)",0.8,Accept,Experimental Usage,Reverse Transcriptase,Other,,,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,TaqMan Universal PCR Master Mix was then performed on an ABI PRISM 7900 Cycler (Applied Biosystems),0.8,Accept,Experimental Usage,PCR Master Mix,Other,,,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,The Nf1 gene was inactivated in passage 1 Nf1flox/flox astrocytes by infection with adenovirus (Ad5) containing Cre recombinase,0.9,Accept,Experimental Usage,Cre,Viral,Ad5,,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,Control Nf1flox/flox astrocytes (wild-type) were treated identically with an adenovirus encoding LacZ,0.9,Accept,Experimental Usage,LacZ,Viral,Ad5,,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,"Target sequencing was performed using the Haloplex custom target enrichment system (Agilent Technologies, CA, USA) on the MiSeq sequencing platform",0.85,Accept,Experimental Usage,RASopathy gene panel,Other,,,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,"We introduced a single-base substitution into the corresponding expression vector using Q5® Site-Directed Mutagenesis Kit (NEB, UK)",0.85,Accept,Experimental Usage,Site-directed mutagenesis reagents,Other,,,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,"We introduced pGal-LUC (Clontech), pGal-ELK1 and the expression plasmids into HEK-293T cells",0.85,Accept,Experimental Usage,Luciferase reporter,Plasmid,,Gal4,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,"We introduced pGal-LUC (Clontech), pGal-ELK1 and the expression plasmids into HEK-293T cells",0.85,Accept,Experimental Usage,ELK1,Plasmid,,Gal4,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,"The luciferase activity was measured using a Dual-Luciferase® Reporter assay system (Promega, WI, USA)",0.85,Accept,Experimental Usage,Dual luciferase reporter,Other,,,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,"Transfection efficiencies were normalised to the control plasmid, which was pSV-RLuc (Promega, WI, USA) expressing Renilla luciferase",0.85,Accept,Experimental Usage,Renilla luciferase,Plasmid,,SV40,,,Renilla luciferase,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,"the in-frame coding sequence of RAF1, A2ML1 and RIT1 were subcloned into the pCMV6-AC-GFP vector such that the GFP coding sequence was fused in-frame",0.85,Accept,Experimental Usage,GFP fusion vector,Plasmid,pCMV6-AC-GFP,CMV,,,GFP,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,"GFP-tagged RNA transcripts were synthesised using the mMESSAGE mMACHINE T7 Transcription Kit (Thermo Fisher Scientific, MA, USA)",0.85,Accept,Experimental Usage,T7 transcription reagents,Other,,,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,"PFA fixed embryos were probed with digoxigenin-labelled cmlc1, which is a cardiac development marker for zebrafish, by in situ hybridization",0.85,Accept,Experimental Usage,cmlc1 probe,Other,,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,mApple-N1 (Addgene plasmid no. 54567) was a gift from M. Davidson,0.9,Accept,Experimental Usage,mApple,Plasmid,,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,pSK ZO-1 (Addgene plasmid no. 30316) was a gift from J. Anderson and A. Fanning,0.9,Accept,Experimental Usage,ZO-1,Plasmid,,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,CMV-GFP-NMHC II-B (Addgene plasmid no. 11348) was a gift from R. Adelstein,0.9,Accept,Experimental Usage,GFP-NMHC II-B,Plasmid,,CMV,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,pGFP(C3)-vinculin (Addgene plasmid no. 30312) was a gift from K. Hahn,0.9,Accept,Experimental Usage,GFP-vinculin,Plasmid,,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,pKvenus-Scrib (Addgene plasmid no. 58738) was a gift from I. Macara,0.9,Accept,Experimental Usage,venus-Scrib,Plasmid,,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,"pEGFP-C3-hYAP1 and pEGFP C3-Lats1 (Addgene plasmid nos. 19053 and 17843, respectively) were gifts from M. Sudol",0.9,Accept,Experimental Usage,EGFP-hYAP1,Plasmid,,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,"pEGFP-C3-hYAP1 and pEGFP C3-Lats1 (Addgene plasmid nos. 19053 and 17843, respectively) were gifts from M. Sudol",0.9,Accept,Experimental Usage,EGFP-Lats1,Plasmid,,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,HA-AMOT p130 (Addgene plasmid no. 32821) was a gift from K. Guan,0.9,Accept,Experimental Usage,HA-AMOT p130,Plasmid,,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,pcDNA3.1-ccdB-NLuc (Addgene plasmid no. 87067) was a gift from M. Taipale,0.9,Accept,Experimental Usage,NLuc,Plasmid,pcDNA3.1,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,p4XBS2WT-Luc (Addgene plasmid no. 16593) was a gift from B. Vogelstein,0.9,Accept,Experimental Usage,4XBS2WT-Luc,Plasmid,,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,p8xGTIIC-luciferase (Addgene plasmid no. 34615) was a gift from S. Piccolo,0.9,Accept,Experimental Usage,8xGTIIC-luciferase,Plasmid,,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,pcDNA3 p53 WT (Addgene plasmid no. 69003) was a gift from D. Meek,0.9,Accept,Experimental Usage,p53 WT,Plasmid,pcDNA3,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,"The Tet-inducible plasmids, pTRE3G-BI-ZsGreen and pCMV-Tet3G, were purchased from Tanaka Holdings",0.85,Accept,Experimental Usage,ZsGreen,Plasmid,pTRE3G-BI,,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,"The Tet-inducible plasmids, pTRE3G-BI-ZsGreen and pCMV-Tet3G, were purchased from Tanaka Holdings",0.85,Accept,Experimental Usage,Tet3G,Plasmid,,CMV,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,HA-H-RAS was expressed together with either wild-type (WT) or variant NF in COS-7 or HEK 293 T cells,0.85,Accept,Experimental Usage,H-RAS,Plasmid,,,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,FLAG-SPRED1 (WT or variant) and NF (WT or variant) were coexpressed in HEK 293 T cells,0.85,Accept,Experimental Usage,SPRED1,Plasmid,,,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,GTP-bound RAS was subsequently isolated using glutathione-agarose beads coated with recombinant GST-RAF-RBD,0.85,Accept,Experimental Usage,RAF-RBD,Other,,,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"AT101 was provided by Ascenta Therapeutics (Malvern, PA)",0.8,Accept,Experimental Usage,AT101,,,,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,BNIP3 and HIF-1α siRNA (siGENOME SMARTPool) was purchased from Thermo Scientific,0.85,Accept,Experimental Usage,BNIP3,Other,,,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,BNIP3 and HIF-1α siRNA (siGENOME SMARTPool) was purchased from Thermo Scientific,0.85,Accept,Experimental Usage,HIF-1α,Other,,,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"Trp53 Exon 3, F AAGTCACAGCACATGACGG",0.9,Accept,Experimental Usage,Trp53,Other,,,,,,,AAGTCACAGCACATGACGG
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"Brca1 Exon 6, F GCGTCGATCATCCAGAGCGT",0.9,Accept,Experimental Usage,Brca1,Other,,,,,,,GCGTCGATCATCCAGAGCGT
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"Nf1 Exon 8, F CCAGGACATCTCCAAGGATG",0.95,Accept,Experimental Usage,Nf1,Other,,,,,,,CCAGGACATCTCCAAGGATG
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"Pten Exon 6, R ATATACATAGCGCCTCTGAC",0.9,Accept,Experimental Usage,Pten,Other,,,,,,,ATATACATAGCGCCTCTGAC
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,"blood was collected in PAXgene whole blood samples (Becton Dickinson, Franklin Lakes, NJ, USA)",0.85,Accept,Experimental Usage,PAXgene,Other,,,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,"extraction was carried out with the PAXgene™ Blood RNA System (Qiagen, Hilden, Germany)",0.85,Accept,Experimental Usage,PAXgene Blood RNA System,Other,,,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,"library preparation with a Haloplex HS or SureSelect kits (Agilent Technologies, Santa Clara, CA, USA)",0.85,Accept,Experimental Usage,Haloplex HS,Other,,,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,"library preparation with a Haloplex HS or SureSelect kits (Agilent Technologies, Santa Clara, CA, USA)",0.85,Accept,Experimental Usage,SureSelect,Other,,,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,"using the SALSA MLPA kits P081/P082 (MRC Holland, Amsterdam, The Netherlands)",0.9,Accept,Experimental Usage,SALSA MLPA P081/P082,Other,,,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,"using the Gentra Puregene kit (Puregene Cell and Tissue kit plus Qiagen GmbH, Hilden, Germany)",0.85,Accept,Experimental Usage,Gentra Puregene,Other,,,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,"cloned into the beta-globin vector, as previously described",0.9,Accept,Experimental Usage,beta-globin,Plasmid,,,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,"transfected with 1 µg of the wild type or the mutated minigene using Lipofectamine 2000 (ThermoFisher Scientific, Watham, MA, USA)",0.85,Accept,Experimental Usage,Lipofectamine 2000,Other,,,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,"total RNA was extracted with TRIzolTM (ThermoFisher Scientific, Watham, MA, USA)",0.85,Accept,Experimental Usage,TRIzol,Other,,,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,"retrotranscribed using SuperScript II reverse transcriptase (ThermoFisher Scientific, Watham, MA, USA)",0.85,Accept,Experimental Usage,SuperScript II,Other,,,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,"purified bands were subcloned using the TOPO TA Cloning kit (ThermoFisher Scientific, Watham, MA, USA)",0.85,Accept,Experimental Usage,TOPO TA,Plasmid,,,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,"we used Phusion polymerase (M0530S; New England Biolabs, Inc., Ipswitch, MA) to synthesize a gRNA in vitro transcription template",0.85,Accept,Experimental Usage,Phusion polymerase,,,,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,used for in vitro transcription of gRNA according to the manufacturer instructions (MEGAshortscript T7 Transcription Kit (AM1354); ThermoFisher Scientific,0.85,Accept,Experimental Usage,T7 transcription,,,,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,1.95μm Cas9 (Cas9 Nuclease V3; IDT),0.9,Accept,Experimental Usage,Cas9,Other,,,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,"PCR was performed using Q5® Hot Start High-Fidelity DNA Polymerase (New England Biolabs, Inc.) according to manufacturer's suggestions",0.85,Accept,Experimental Usage,Q5 DNA polymerase,,,,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,"the targeted region was PCR amplified with the hotstart PrimeSTAR GXL DNA polymerase (Takara Bio Inc., Mountain View, CA)",0.85,Accept,Experimental Usage,PrimeSTAR GXL,,,,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,"The injection solution contained gRNAs, S. pyogenes Cas9 mRNA (PNA Bio Inc., Thousand Oaks, CA or Millipore Sigma, Burlington, MA)",0.9,Accept,Experimental Usage,Cas9,Other,,,S. pyogenes,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",0.9,Accept,Development,dll4,,,hsp70,,,GFP,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",0.9,Accept,Development,dlb,,,hsp70,,,GFP,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",0.9,Accept,Development,hey1,,,hsp70,,,GFP,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",0.9,Accept,Development,id2b,,,hsp70,,,GFP,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",0.9,Accept,Development,Cas9,,,ubi,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",0.9,Accept,Development,dll4-gRNAs,,,u6,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",0.9,Accept,Development,n3-gRNAs,,,u6,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,A 3kb region upstream of the hey1 gene's transcription start site was amplified by PCR and cloned into Xho1/Kpn1 sites of the pXP1 plasmid to create 3kb-hey1:luciferase,0.9,Accept,Development,hey1,,pXP1,,,,luciferase,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"we generated pCS2+dlb-EGFP, pCS2+n3-EGFP and pCS2+id2b-EGFP constructs",0.9,Accept,Development,dlb,,pCS2,,,,EGFP,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"we generated pCS2+dlb-EGFP, pCS2+n3-EGFP and pCS2+id2b-EGFP constructs",0.9,Accept,Development,n3,,pCS2,,,,EGFP,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"we generated pCS2+dlb-EGFP, pCS2+n3-EGFP and pCS2+id2b-EGFP constructs",0.9,Accept,Development,id2b,,pCS2,,,,EGFP,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,"NHE1 siRNA: ON-TARGET SMART pool (Thermo Scientific); NBCn1 siRNA (SASI_Hs01_00030755, Sigma-Aldrich)",0.85,Accept,Experimental Usage,NHE1,Other,,,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,"Merlin siRNA (SASI_Hs_01_00188862, Sigma) sense sequence 5′-CCUCAAAGCUUCGUGUUAA-3",0.9,Accept,Experimental Usage,Merlin,Other,,,,,,,5′-CCUCAAAGCUUCGUGUUAA-3′
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"full length cDNA coding sequence of NF2 (isoform 1, NCBI accession # NM_000268) cloned into the lentiviral vector CSCW2",0.9,Accept,Experimental Usage,NF2,Viral,CSCW2,,Human,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Ben-Men-1 cells were transduced with either NF2-CSCW2 or V-CSCW2,0.8,Accept,Experimental Usage,V-CSCW2,Viral,CSCW2,,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)",0.85,Accept,Experimental Usage,INK128,,,,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)",0.85,Accept,Experimental Usage,TAK-228,,,,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)",0.85,Accept,Experimental Usage,BMS-754807,,,,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)",0.85,Accept,Experimental Usage,lapatinib,,,,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)",0.85,Accept,Experimental Usage,erlotinib,,,,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,rapamycin (EMD Millipore),0.85,Accept,Experimental Usage,rapamycin,,,,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,AZD2014 (obtained from AstraZeneca),0.85,Accept,Experimental Usage,AZD2014,,,,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,MM-121 (generously provided by Merrimack Pharmaceuticals),0.85,Accept,Experimental Usage,MM-121,,,,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Drug screening assays for all cell lines were carried out in a 384-well format using the CellTiter-Glo cell viability kit (Promega),0.9,Accept,Experimental Usage,CellTiter-Glo cell viability kit,,,,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"50 μg of the STING agonist ADU-S100 (HY-12885B, MedChemExpress)",0.9,Accept,Experimental Usage,ADU-S100,,,,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"mice that were treated with the STING agonist SA3 (HY-103665, MedChemExpress)",0.9,Accept,Experimental Usage,SA3,,,,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,pscAAV-GFP and pscAAV-GRDC24 (2163 bp between ITRs) were used to generate AAV-GFP and AAV-GRDC24,0.9,Accept,Development,GRDC24,Viral,AAV,CBh,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,"This tailored vector, AAV-NF, exhibits greatly reduced liver uptake, enhanced tumor targeting across various NF1-related MPNST",0.95,Accept,Development,NF-targeting capsid,Viral,AAV,,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,"MPNST cells were seeded in 15-cm dishes, allowed cell attachment overnight, treated the next day with the desired drug concentrations, harvested at the experiment endpoint, and lysed using the lysis buffer provided by Human Phospho-RTK Array Kit (R&D)",0.85,Accept,Experimental Usage,Human Phospho-RTK Array,Other,,,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,"The LentiCRISPR-v2 (RRID: Addgene_52961), LentiGuide-Puro (RRID: Addgene_52963), and LentiCas9-Blast (RRID: Addgene_52962) vectors were purchased from Addgene",0.95,Accept,Experimental Usage,CRISPR-Cas9,Viral,LentiCRISPR-v2,,,,Puromycin,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,"The LentiCRISPR-v2 (RRID: Addgene_52961), LentiGuide-Puro (RRID: Addgene_52963), and LentiCas9-Blast (RRID: Addgene_52962) vectors were purchased from Addgene",0.95,Accept,Experimental Usage,Guide RNA,Viral,LentiGuide-Puro,,,,Puromycin,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,"The LentiCRISPR-v2 (RRID: Addgene_52961), LentiGuide-Puro (RRID: Addgene_52963), and LentiCas9-Blast (RRID: Addgene_52962) vectors were purchased from Addgene",0.95,Accept,Experimental Usage,Cas9,Viral,LentiCas9-Blast,,,,Blasticidin,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,WT S2R+ cells were co‐transfected with the pl018 plasmid to express Cas9,0.85,Accept,Experimental Usage,Cas9,Plasmid,,,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,co‐transfected with the pl018 plasmid to express Cas9 and the sgRNA (CGCTTCTCCCTTGTCATATC) and pAct‐GFP plasmid,0.85,Accept,Experimental Usage,GFP,Plasmid,,Actin,,,GFP,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"NF1‐sg2 (ACACTGGAAAAATGTCTTGC), a sgRNA targeting human NF1 exon 3 in the lentiCRISPR v1 plasmid",0.9,Accept,Experimental Usage,CRISPR-Cas9,Plasmid,,,,,Puromycin,,ACACTGGAAAAATGTCTTGC
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,The UAS‐dNf1 transgene encodes full‐length dNf1 cDNA corresponding to the RF isoform,0.9,Accept,Experimental Usage,dNf1,Transposon,,UAS,Drosophila,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,"Sequencing libraries were generated from 1 μg genomic DNA using Agilent SureSelect Human All Exon kit (Agilent Technologies, California, USA)",0.85,Accept,Experimental Usage,Human All Exon capture probes,Other,,,,,,,
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,These cell lines have been transduced with lentivirus expressing Fluc and mCherry genes as described previously,0.85,Accept,Experimental Usage,Fluc and mCherry,Viral,,,,,mCherry,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,"The deletions analyzed in this study were identified by MLPA analysis (P122-C1 NF1-area kit, MRC-Holland, The Netherlands)",0.85,Accept,Experimental Usage,NF1-area probes,Other,,,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,"Breakpoint-spanning PCRs were performed using the Expand Long Template PCR system (Roche, Mannheim, Germany)",0.8,Accept,Experimental Usage,Long Template PCR enzymes,Other,,,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,"sequenced with the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies, Darmstadt, Germany)",0.8,Accept,Experimental Usage,BigDye Terminator,Other,,,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,"To perform GenomeWalker™ analysis (Clontech, Saint-Germain-en-Laye, France), genomic DNA (2.5 μg per experiment) was restriction digested",0.8,Accept,Experimental Usage,GenomeWalker adaptors,Other,,,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,PCRs were performed with the Advantage® 2 PCR Kit (Clontech),0.8,Accept,Experimental Usage,Advantage 2 PCR enzymes,Other,,,,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"We studied a fluorine-18 labeled tryptophan positron emission tomography (PET) radiotracer, 1-(2-[18F]FETrp",0.9,Accept,Experimental Usage,L-[18F]FETrp,,,,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,Phospho-proteins were isolated from cell lysates using the commercially available phospho-protein purification kit from Qiagen®,0.8,Accept,Experimental Usage,phospho-protein purification kit from Qiagen®,,,,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,Five different shRNA clones were tested... cloned into the plasmid pLKO.1-puro,0.9,Accept,Experimental Usage,PDLIM2 shRNA,Plasmid,pLKO.1-puro,,,,Puromycin,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,Protein dephosphorylation was achieved by treating 20 μg of protein lysate with λ-phosphatase (New England Biolabs),0.85,Accept,Experimental Usage,λ-phosphatase,,,,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,"To ascertain the cellular location of PDLIM2, a cytoplasmic and nuclear extraction assay (Thermo Scientific) was performed",0.8,Accept,Experimental Usage,cytoplasmic and nuclear extraction assay (Thermo Scientific),,,,,,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,"We then prepared lentivirus vector pLentiCre/gRNA, which could express the elements blocking the function of four genes: Nf2, P15",0.9,Accept,Development,Cre and gRNAs,Viral,pLenti,CMV,,,GFP,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,"we constructed an AAV vector of pAAVCre/gRNA, which could import Cre and the four gRNAs",0.9,Accept,Development,Cre and gRNAs,Viral,AAV,pEFS,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,"0.25 units of Taq polymerase (Perkin-Elmer Cetus) and a mixture of dATP, dCTP, dGTP and dTTP",0.8,Accept,Experimental Usage,Taq polymerase,,,,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,"200 ng of each oligonucleotide primer (NeoTkp, NF31a, NF31b)",0.85,Accept,Experimental Usage,NeoTkp,,,,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,"200 ng of each oligonucleotide primer (NeoTkp, NF31a, NF31b)",0.85,Accept,Experimental Usage,NF31a,,,,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,"200 ng of each oligonucleotide primer (NeoTkp, NF31a, NF31b)",0.85,Accept,Experimental Usage,NF31b,,,,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,Embryos were decapitated in Leibovitz's L15 medium (Gibco),0.75,Accept,Experimental Usage,Leibovitz's L15 medium,,,,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,"transferred to approximately 10 ml of Dulbecco's Modified Eagle Medium (DMEM, Gibco)",0.75,Accept,Experimental Usage,DMEM,,,,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,"50 ng/ml nerve growth factor [2.5S NGF, Harlan Bio-products]",0.8,Accept,Experimental Usage,2.5S NGF,,,,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,"amplified for 1 week in recombinant human glial growth factor (rhGGF2, Cambridge Neuroscience)",0.8,Accept,Experimental Usage,rhGGF2,,,,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,the plasmid pcNf2hflag containing a CMV promoter and a neomycin resistance cassette was used,0.9,Accept,Experimental Usage,Nf2,Plasmid,,CMV,,,neomycin,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,An empty vector pcDNA3.1 was used as a control,0.85,Accept,Experimental Usage,empty vector,Plasmid,pcDNA3.1,,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"MPNST cells were infected with purified Ad-NF1-GRD or control Ad-GFP, in triplicate, for 2 h in serum-free medium",0.9,Accept,Experimental Usage,NF1-GRD,Viral,Adenovirus,,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"MPNST cells were infected with purified Ad-NF1-GRD or control Ad-GFP, in triplicate",0.85,Accept,Experimental Usage,GFP,Viral,Adenovirus,,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Constitutive expression used mCherry tagged MAF (EX-Y2046-Lv111, GeneCopoeia) and mCherry control lentivirus",0.95,Accept,Experimental Usage,MAF,Viral,Lentivirus,,,,mCherry,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,Inducible expression used lentiviral vectors containing the MAF ORF or empty pLVX-Tight-Puro vector (GeneCopoeia),0.9,Accept,Experimental Usage,MAF ORF,Viral,pLVX-Tight-Puro,,,,Puromycin,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,in a modified pTight backbone (Clonetech) with pLVX-Tet-On doxycycline inducible vector (Clonetech),0.9,Accept,Experimental Usage,Tet-On,Viral,pLVX,Tet-inducible,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,Cells were transfected using FuGENE HD (Roche) with 100ng per well of an AP-1 luciferase (Stratagene) reporter vector,0.9,Accept,Experimental Usage,AP-1 luciferase,Plasmid,,AP-1,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,"Genomic DNA was extracted from the peripheral blood, skin lesions, hair, oral mucosa, and tumor tissues separately using the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen, Corning, Jiangsu, China)",0.85,Accept,Experimental Usage,DNA extraction reagent,Other,,,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,"Genomic DNA was extracted from the peripheral blood, skin lesions, hair, oral mucosa, and tumor tissues separately using the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen, Corning, Jiangsu, China) and DNeasy Blood & Tissue Kit (Qiagen, Germany)",0.85,Accept,Experimental Usage,DNA extraction reagent,Other,,,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,"quantified with a Qubit 2.0 Fluorometer using the Qubit dsDNA HS Assay Kit (Life Technologies, Thermo Fisher Scientific, Inc.)",0.85,Accept,Experimental Usage,DNA quantification reagent,Other,,,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,the capture probe from the Roche NimbleGen Sequence Capture SeqCap EZ Library was used to capture a total of 569 genes associated with hereditary dermatosis,0.9,Accept,Experimental Usage,capture probe library,Other,,,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,AURKA specific inhibitor MLN8237 (Selleck Chemicals). Mice were treated by gavage once daily with 30mg/kg MLN8237,0.8,Accept,Experimental Usage,MLN8237,,,,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,Small-molecule AKIs were dissolved and diluted in DMSO/DMEM and included the pan-aurora inhibitors C1368 (Sigma),0.75,Accept,Experimental Usage,C1368,,,,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,pan-aurora inhibitors C1368 (Sigma) and VX680 (Selleck Chemicals),0.75,Accept,Experimental Usage,VX680,,,,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,"Lentivirus packaging, envelope and control non-hairpin (NHP) pLKO.1 plasmids (Addgene)",0.85,Accept,Experimental Usage,pLKO.1,Plasmid,pLKO.1,,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,shRNA against RHAMM and TPX2 (Sigma),0.85,Accept,Experimental Usage,shRHAMM,Viral,,,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,shRNA against RHAMM and TPX2 (Sigma),0.85,Accept,Experimental Usage,shTPX2,Viral,,,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"For siRNA knockdown targeting ZEB1 (Sigma-Aldrich, SASI_Hs02_00330526, SASI_Hs02_00330527, SASI_Hs02_00330530)",0.9,Accept,Experimental Usage,ZEB1,Other,,,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"ALDH1A1 (Sigma-Aldrich, SASI_Hs01_00244055, SASI_Hs01_00244056, SASI_Hs02_00303091) in MPNST cell lines",0.9,Accept,Experimental Usage,ALDH1A1,Other,,,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"T265, was infected by nontarget control or lentiviral vectors carrying ZEB1 shRNA lentivirus for 48 hours",0.85,Accept,Experimental Usage,ZEB1,Viral,,,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,we utilized CRISPR Cas9 targeting of NF1 exon 2 to create inactivating indels in NF1 on both alleles,0.85,Accept,Experimental Usage,Cas9,Other,,,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,"The wild type (WT) mNf1 cDNA plasmid was developed by GeneCopoeia and is commercially available. The full-length, endogenous mouse cDNA (mNf1) containing Nf1 isoform 2",0.9,Accept,Experimental Usage,Nf1,Plasmid,,,Mouse,,G418,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,"We utilized a StepTactin XT System from IBA Lifesciences (Gottingen, Germany). Whole cell lysates were generated by collecting cells and lysing them",0.85,Accept,Experimental Usage,StrepII tag,Other,,,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,"Global protein extracts were attained using M-PER™ Mammalian Protein Extraction Reagent (Thermo Fisher Scientific, Cat.# 78501)",0.8,Accept,Experimental Usage,M-PER,Other,,,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,"and quantified using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Cat.# PI23225)",0.8,Accept,Experimental Usage,BCA,Other,,,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,TALENs were designed to flank the region of NF1 in exon 41. Ossabaw minipig fetal fibroblasts isolated from day 38 embryos were transfected with TALENs,0.85,Accept,Experimental Usage,NF1-targeting TALEN,Other,,,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,DNA was isolated from harvested tissues using DNeasy blood and tissue kit (Qiagen) according to the manufacturer's protocol,0.75,Accept,Experimental Usage,DNA extraction kit,,,,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Total RNA was extracted from cells and tissues using the RNeasy mini kit (Qiagen) following manufacturer's instructions,0.75,Accept,Experimental Usage,RNA extraction kit,,,,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Proliferation was evaluated by the alamarBlue TM cell viability assay (Invitrogen) after indicated days in culture,0.8,Accept,Experimental Usage,alamarBlue,,,,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Gentamicin (Sigma) and G418 (Corning) were reconstituted in sterile deionized water to a stock concentration of 50 mg/mL,0.9,Accept,Experimental Usage,Gentamicin,,,,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Gentamicin (Sigma) and G418 (Corning) were reconstituted in sterile deionized water,0.9,Accept,Experimental Usage,G418,,,,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Ataluren (MedChem Express) was reconstituted in sterile dimethyl sulfoxide (DMSO) to a stock concentration of 10 mM,0.9,Accept,Experimental Usage,Ataluren,,,,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,The NF1 DLR plasmid was kindly provided by David Bedwell at University of Alabama. The R1497X Renilla-NF1-R1947X-Firefly insert contains 30 nucleotides,0.95,Accept,Experimental Usage,NF1 DLR,Plasmid,,,Human,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,we used Gateway cloning to transfer the DLR insert to a hygromycin-resistant PiggyBac Sleeping Beauty (PBSB) transposon vector,0.85,Accept,Experimental Usage,PBSB,Transposon,,,,,Hygromycin,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,"cells were transfected with 50 nm of siRNA targeting UPF1. In a pilot experiment, three custom and non-overlapping UPF1 duplexes were tested",0.9,Accept,Experimental Usage,UPF1,Other,,,,,,,CUGUAAUGGACGUGGAAAUUU
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,EdU proliferation assay was performed using the Click-iT EdU Alexa Fluor 594 imaging kit (Thermo Fisher Scientific C10339),0.8,Accept,Experimental Usage,EdU,,,,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,Glutamate released from wild-type and Nf1 cortical neurons was measured using the Amplex Red glutamic acid/glutsamate oxidase assay kit (Invitrogen),0.9,Accept,Experimental Usage,Amplex Red glutamic acid/glutamate oxidase assay,,,,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,Neurite outgrowth was determined from low-density hippocampal neurons transfected with EGFP using Lipofectamine,0.9,Accept,Experimental Usage,EGFP,,,,,,GFP,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,Neurite outgrowth was determined from low-density hippocampal neurons transfected with EGFP using Lipofectamine,0.85,Accept,Experimental Usage,Lipofectamine,Other,,,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"DNA was extracted from fresh-frozen tumor tissue and normal tissue using the DNeasy Blood and Tissue Kit (Qiagen, USA)",0.85,Accept,Experimental Usage,DNA extraction reagent,Other,,,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"Total RNA was isolated from tumor using the RNeasy Mini Kit (Qiagen, USA)",0.85,Accept,Experimental Usage,RNA extraction reagent,Other,,,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"To generate CRISPR/Cas9-modified ipNF06.2A cell lines, sequences were subcloned into pX330",0.9,Accept,Experimental Usage,Cas9,Plasmid,pX330,,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,Wild-type and Nf1 −/− NSCs were generated from Nf1 flox/flox mouse brains following infection with Ad5-LacZ and Ad5-Cre adenovirus,0.85,Accept,Experimental Usage,LacZ,Viral,Ad5,,Mouse,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,Wild-type and Nf1 −/− NSCs were generated from Nf1 flox/flox mouse brains following infection with Ad5-LacZ and Ad5-Cre adenovirus,0.85,Accept,Experimental Usage,Cre,Viral,Ad5,,Mouse,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,"Abcg1 shRNA or control shGFP-containing pLKO.1 plasmid was co-transfected with pMDLg/pRRE, pRSV-REV and pCMV-VSV-G",0.85,Accept,Experimental Usage,Abcg1,Plasmid,pLKO.1,,Mouse,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,Abcg1 shRNA or control shGFP-containing pLKO.1 plasmid was co-transfected,0.8,Accept,Experimental Usage,shRNA,Plasmid,pLKO.1,,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems",0.85,Accept,Experimental Usage,GSK3B,Viral,,,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems",0.85,Accept,Experimental Usage,AXIN1,Viral,,,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems",0.85,Accept,Experimental Usage,CTNNB1,Viral,,,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems",0.85,Accept,Experimental Usage,TNKS,Viral,,,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems",0.85,Accept,Experimental Usage,RSPO2,Viral,,,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,A dsRed control and CTNNB1 S33Y were cloned into a vector containing a CAGGS promoter to drive cDNA expression followed by an IRES-GFP,0.85,Accept,Experimental Usage,CTNNB1 S33Y,Viral,,CAGGS,,,GFP,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,GSK3B and Luciferase cDNA (Invitrogen) were each cloned into a vector containing a CAGGS promoter to drive cDNA expression followed by an IRES-GFP,0.85,Accept,Experimental Usage,GSK3B,Plasmid,,CAGGS,,,GFP,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,The control mice used in this study are a pool of phenotypically indistinguishable mice with genotypes of hGFAP-cre-; Nf1 flox/flox,0.9,Accept,Experimental Usage,hGFAP-cre,Other,,,Human,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,"mice with genotypes of hGFAP-cre-; Nf1 flox/flox , hGFAP-cre-; Nf1 flox/+ , hGFAP-cre+; Nf1 flox/+",0.95,Accept,Experimental Usage,Nf1 flox,,,,Mouse,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,"hGFAP-cre±; Nf1 KO/+ . The mutant mice ( Nf1 hGFAP CKO) used were of the genotypes, hGFAP-cre+; Nf1 flox/KO",0.9,Accept,Experimental Usage,Nf1 KO,,,,Mouse,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,"For inducible experiments, Nestin-cre ER +; Nf1 flox/+  (tamoxifen+) mice were used as controls while Nestin-cre ER +; Nf1 flox/flox",0.9,Accept,Experimental Usage,Nestin-cre ER,,,,Mouse,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Both of inducible strains carry R26 LacZR  allele as a reporter.,0.85,Accept,Experimental Usage,R26 LacZR,,,,Mouse,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,"MEK inhibitor (PD0325901, Sigma) was dissolved in DMSO at a concentration of 25mg/ml",0.9,Accept,Experimental Usage,PD0325901,,,,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"Human HK2 recombinant protein (0.5 μg; HXK0703, ATGEN) or total cell lysate",0.9,Accept,Experimental Usage,HK2,,,,Human,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,cells were transfected with the ER‐targeted D4ER Ca2+ probe,0.9,Accept,Experimental Usage,D4ER,,,,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,cells were transfected with a cDNA encoding mitochondrial and nuclear GCAMP6f,0.9,Accept,Experimental Usage,GCAMP6f,,,,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,cells were transfected with a plasmid encoding low‐affinity mitochondrial matrix aequorin (mit‐Aeqmut),0.9,Accept,Experimental Usage,mit-Aeqmut,,,,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,cells were transfected with a plasmid encoding the GFP‐tagged pleckstrin homology (PH) domain of PLC‐δ1 (GFP‐PHD),0.9,Accept,Experimental Usage,GFP-PHD,,,,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,"cfDNA was extracted from 2 to 8 mL of plasma using the QIAamp Circulating Nucleic Acid kit (Qiagen, Hilden, Germany)",0.85,Accept,Experimental Usage,cfDNA extraction reagent,Other,,,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,"germline DNA extraction using the DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany)",0.85,Accept,Experimental Usage,DNA extraction reagent,Other,,,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,"germline DNA from PBMCs was collected in and extracted using PAXgene Blood DNA tubes and kit (PreAnalytix, Germantown, Maryland)",0.85,Accept,Experimental Usage,DNA extraction reagent,Other,,,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,"Nucleic acids were isolated from tumor FFPE samples using the manufacturer's protocol with the AllPrep DNA/RNA FFPE kit (Qiagen, Hilden, Germany)",0.85,Accept,Experimental Usage,DNA/RNA extraction reagent,Other,,,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,"Sequencing libraries were constructed from cfDNA using commercial kits per the manufacturers' instructions: TruSeq Nano (Illumina, San Diego, California)",0.85,Accept,Experimental Usage,library preparation reagent,Other,,,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,"Sequencing libraries were constructed using commercial kits: Kapa HyperPrep (Roche, Basel, Switzerland) for WUSTL samples",0.85,Accept,Experimental Usage,library preparation reagent,Other,,,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,sgRNA1 (5′-TAACTGCGCAACCTTCTTTA-3′) and sgRNA2 (5′-GTTAGCAGTTATAAATAGCC-3′) target the exon 6 of NF1 gene,0.95,Accept,Experimental Usage,NF1,,,,Human,,,,5′-TAACTGCGCAACCTTCTTTA-3′
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,sgRNA1 (5′-TAACTGCGCAACCTTCTTTA-3′) and sgRNA2 (5′-GTTAGCAGTTATAAATAGCC-3′) target the exon 6 of NF1 gene,0.95,Accept,Experimental Usage,NF1,,,,Human,,,,5′-GTTAGCAGTTATAAATAGCC-3′
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"GFP-tagged human neurofibromin, transcript variant 1 cDNA (RG220425, Origene)",0.95,Accept,Experimental Usage,human neurofibromin,Plasmid,,,Human,,GFP,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"Myc-DDK–tagged human FBXW11 transcript variant 3 cDNA (RC218905, Origene)",0.95,Accept,Experimental Usage,human FBXW11,Plasmid,,,Human,,Myc-DDK,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"control (GFP; AAV5-CMV-GFP, UNC) or Cre-recombinase fused to GFP (CRE; AAV5-CMV-Cre-GFP, UNC)",0.95,Accept,Experimental Usage,GFP,Viral,AAV5,CMV,,,GFP,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"control (GFP; AAV5-CMV-GFP, UNC) or Cre-recombinase fused to GFP (CRE; AAV5-CMV-Cre-GFP, UNC)",0.95,Accept,Experimental Usage,Cre-GFP,Viral,AAV5,CMV,,,GFP,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,TRAP1 and CyPD expression were knocked out using the lenti CRISPRv2 system,0.9,Accept,Experimental Usage,CRISPRv2,Viral,lentiCRISPRv2,,,,Puromycin,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,"cloned into the transfer plasmid lentiCRISPRv2 (Addgene, https://www.addgene.org/52961/)",0.95,Accept,Experimental Usage,lentiCRISPRv2,Plasmid,lentiCRISPRv2,,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,The human CypD expression system was constructed by building the pSUMO-Cyclophilin D plasmid,0.85,Accept,Experimental Usage,Cyclophilin D,Plasmid,pSUMO,,Human,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,co-transfected with a combination of plasmids pcDNA3 mito-GFP1-9,0.85,Accept,Experimental Usage,mito-GFP1-9,Plasmid,pcDNA3,,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,pcDNA3-TRAP1-GFP10,0.85,Accept,Experimental Usage,TRAP1-GFP10,Plasmid,pcDNA3,,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,pcDNA3CyPD-GFP11,0.85,Accept,Experimental Usage,CyPD-GFP11,Plasmid,pcDNA3,,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,pcDNA3ATP50-GFP11,0.85,Accept,Experimental Usage,ATP50-GFP11,Plasmid,pcDNA3,,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,An FDA-approved small molecule MEK inhibitor (either trametinib or selumetinib) was used off-label to treat nine patients,0.8,Accept,Experimental Usage,trametinib,,,,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,An FDA-approved small molecule MEK inhibitor (either trametinib or selumetinib) was used off-label to treat nine patients,0.8,Accept,Experimental Usage,selumetinib,,,,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"Total RNA, including miRNA was extracted using the miRNAeasy kit (Qiagen Ltd, Crawley, West Sussex, UK)",0.9,Accept,Experimental Usage,miRNAeasy kit,,,,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,Hundred nanogram of total RNA per sample was labelled and hybridised to the Agilent Human miRNA microarray V2,0.95,Accept,Experimental Usage,Agilent Human miRNA Microarray V2,,,,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"MicroRNA expression in each sample, and the cell line, was measured using TaqMan miRNA assays technology (Applied Biosystems Inc.)",0.9,Accept,Experimental Usage,TaqMan miRNA assays,,,,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"sNF96.2, was transfected in six-well plates using oligofectamine (Invitrogen) giving a final concentration of 100 nM of miRNA mimics (Dharmacon Inc.)",0.9,Accept,Experimental Usage,miR-29c,,,,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,High molecular weight (HMW) DNA (25 µg) was extracted from leukocytes using the Circulomics Nanobind CBB Big DNA kit,0.85,Accept,Experimental Usage,DNA extraction reagent,Other,,,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,Sequencing libraries were prepared from 3 µg of input DNA using the SQK-LSK109 ligation sequencing kit,0.85,Accept,Experimental Usage,sequencing library preparation,Other,,,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,Tumors were mechanically and enzymatically dissociated using a papain-based tumor dissociation kit (Miltenyi Biotec).,0.85,Accept,Experimental Usage,papain,Other,,,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,re-suspended in 1 mL of BSA/HBSS containing 1 mM calcein AM (Life Technologies) and 0.33 mM TO-PRO-3 iodide,0.8,Accept,Experimental Usage,calcein AM,,,,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,re-suspended in 1 mL of BSA/HBSS containing 1 mM calcein AM (Life Technologies) and 0.33 mM TO-PRO-3 iodide (Life Technologies),0.8,Accept,Experimental Usage,TO-PRO-3 iodide,,,,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,"Extraction of DNA from leukocytes and purification were performed with QIAamp DNA Blood Mini kit (Qiagen, Valencia, CA, USA)",0.85,Accept,Experimental Usage,DNA extraction reagent,Other,,,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,Capture probe set was designed and synthesized by Thermo Fisher Scientific for the Ion TargetSeq Custom Enrichment kit,0.9,Accept,Experimental Usage,NF1 capture probes,Other,,,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,"cells were tested for mycoplasma using the Promokine Mycoplasma Test Kit I/C (Minerva Biolabs, Berlin, Germany)",0.8,Accept,Experimental Usage,Mycoplasma detection reagents,,,,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,Cell line identity (short tandem repeat analysis) was performed using the GenePrint 10 System (Promega),0.8,Accept,Experimental Usage,STR analysis reagents,,,,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,HPCs were generated using the STEMdiff hematopoietic kit (STEMCELL Technologies),0.85,Accept,Experimental Usage,Hematopoietic differentiation factors,,,,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,"cells were harvested and RNA was isolated with the ReliaPrep RNA tissue kit (Promega, Fitchburg, USA)",0.85,Accept,Experimental Usage,RNA extraction reagents,,,,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,"RNA was reverse transcribed into cDNA using the PrimeScript RT reagent kit (Takara Bio, Kusatsu, Japan)",0.85,Accept,Experimental Usage,Reverse transcription reagents,,,,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,"Cell motility was assessed using the IncuCyte cell migration kit (Sartorius, Göttingen, Germany)",0.8,Accept,Experimental Usage,Cell migration assay reagents,,,,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,"cAMP levels in hiMGL cells were determined using the cAMP ELISA kit (Cayman Chemical, Ann Arbor, MI, USA)",0.85,Accept,Experimental Usage,cAMP detection reagents,,,,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,"The MILLIPLEX MAP human cytokine/chemokine/growth factor panel A – immunology multiplex assay (HCYTA-60K, Merck) was used",0.85,Accept,Experimental Usage,Cytokine detection reagents,,,,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,"500 ng of DNA from each sample was bisulfite converted using the Zymo EZ DNA Methylation Kit (Zymo Research, Irvine, CA USA)",0.85,Accept,Experimental Usage,DNA methylation conversion reagent,Other,,,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"verteporfin (S1786, Selleckchem) and sorafenib p-Toluenesulfonate salt (S-8502, LC Laboratories) were dissolved in DMSO",0.8,Accept,Experimental Usage,verteporfin,,,,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"verteporfin (S1786, Selleckchem) and sorafenib p-Toluenesulfonate salt (S-8502, LC Laboratories) were dissolved in DMSO",0.8,Accept,Experimental Usage,sorafenib p-Toluenesulfonate salt,,,,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"Dobutamine hydrochloride (D0676, Sigma Aldrich) and imatinib mesylate (I-5508, LC Laboratories) were dissolved in distilled water",0.8,Accept,Experimental Usage,imatinib mesylate,,,,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"Lentiviral vectors expressing NF1 small hairpin (sh) RNA and shCtr were purchased from Sigma (CAT# TRCN000023878, TRCN0000039713, and SHC202)",0.95,Accept,Experimental Usage,NF1 shRNA,Viral,,,Human,,Puromycin,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"Lentiviral vectors expressing NF1 small hairpin (sh) RNA and shCtr were purchased from Sigma (CAT# TRCN000023878, TRCN0000039713, and SHC202)",0.95,Accept,Experimental Usage,NF1 shRNA,Viral,,,Human,,Puromycin,,
PMID:34646065,10.1155/2021/9386823,Survival and ,,"all samples were screened for large deletions using four TaqMan NF1 copy-number assays across the gene (ThermoFisher; Hs05477010, Hs06413401, Hs05512625, and Hs03960106)",0.9,Accept,Experimental Usage,NF1,Other,,,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,We performed exome sequencing on five malignant meningiomas on the Illumina HiSeq2000 platform using Agilent SureSelect Human All Exon kits.,0.9,Accept,Experimental Usage,Human All Exon,Other,,,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,"We next designed custom NimbleGen targeted region arrays on five candidate genes, and sequenced four additional malignant meningiomas.",0.85,Accept,Experimental Usage,targeted region arrays,Other,,,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,"DNA samples were extracted from the tumor FFPE slides from these patients using QIAamp DNA FFPE kit (Qiagen, Valencia, CA, USA)",0.85,Accept,Experimental Usage,DNA FFPE extraction,Other,,,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,"Next, we purified DNA fragments using AMpure XP beads (Beckman, Brea, CA, USA).",0.85,Accept,Experimental Usage,AMpure XP,Other,,,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,"The PCR mixture contained 5 μl of 10X AccuPrime™ PCR Buffer, 0.3 μl of AccuPrime™ Taq High Fidelit",0.85,Accept,Experimental Usage,AccuPrime Taq High Fidelity,Other,,,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,"Genotyping was performed using a real-time PCR system in the allelic discrimination mode...using the TaqMan Genotyping Master Mix (Applied Biosystems, Foster City, CA, USA)",0.85,Accept,Experimental Usage,COMT val158met probe,Other,,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,"Cell lines were transduced with Incucyte Nuclight Red Lentivirus (Sartorius, Gottingen, Germany) such that they will produce an EF1α promoter driven nuclear restricted red fluorescent label",0.9,Accept,Experimental Usage,nuclear RFP,Viral,,EF1α,,,RFP,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"Small interfering RNA (siRNA) molecules (neurofibromin 2 ON-TARGETplus SMARTpool; Dharmacon, Lafayette, CO) were diluted in Opti-MEM",0.95,Accept,Experimental Usage,neurofibromin 2,Other,,,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"Transfection with a non-targeting, random sequence siRNA (Dharmacon) or Lipofectamine ™ 2000 alone served as separate negative controls.",0.85,Accept,Experimental Usage,non-targeting control,Other,,,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"total RNA was harvested with the RNeasy Mini Kit according to manufacturer's instructions (Qiagen Sciences, Germantown, MD)",0.8,Accept,Experimental Usage,RNA extraction kit,Other,,,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"2 μg of RNA was converted to the more stable complimentary deoxyribonucleic acid (cDNA) strands with TaqMan reverse transcription reagents (Applied Biosystems, Foster city, CA)",0.8,Accept,Experimental Usage,reverse transcription reagents,Other,,,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,Cells were then treated with Zymed ® BrdU Staining Kit (Invitrogen),0.8,Accept,Experimental Usage,BrdU staining reagents,Other,,,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"The Annexin V-FITC Apoptosis Detection kit (Calbiochem, San Diego, Cat # PF032) was used following the manufacturer's instructions.",0.8,Accept,Experimental Usage,Annexin V-FITC,Other,,,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"To determine the activity of Ras the EZ-Detect Ras Activation Kit (cat. 89855 from Pierce, Rockford, IL) was used",0.85,Accept,Experimental Usage,Ras Binding Domain,Other,,,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,Viability was assessed using the Cell Counting Kit 8 (CCK8) from Dojindo Molecular Technologies,0.8,Accept,Experimental Usage,CCK8,,,,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"siRNA for either B-Raf: AAAGAATTGGATCTGGATCAT, and C-Raf: TGTGCGAAATGGAATGAGCTT, both from Dharmacon",0.9,Accept,Experimental Usage,B-Raf,Other,,,,,,,AAAGAATTGGATCTGGATCAT
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"siRNA for either B-Raf: AAAGAATTGGATCTGGATCAT, and C-Raf: TGTGCGAAATGGAATGAGCTT, both from Dharmacon",0.9,Accept,Experimental Usage,C-Raf,Other,,,,,,,TGTGCGAAATGGAATGAGCTT
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"Nutlin-3 (# S1778, Beyotime, Shanghai, China), MG-132 (# S1748, Beyotime) and Pifithrin (PFT)-α",0.8,Accept,Experimental Usage,Nutlin-3,Other,,,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"Nutlin-3 (# S1778, Beyotime, Shanghai, China), MG-132 (# S1748, Beyotime) and Pifithrin (PFT)-α",0.8,Accept,Experimental Usage,MG-132,Other,,,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,Lentiviral shRNA vectors were constructed using target sequences against the expression of NF2,0.9,Accept,Experimental Usage,NF2 shRNA,Viral,Lentiviral,,,,,,ACTTCAAAGATA CTG ACAT
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,P53 (5′-GA CTCCA GTGGT AA TCT A C-3′),0.9,Accept,Experimental Usage,P53 shRNA,Viral,Lentiviral,,,,,,GA CTCCA GTGGT AA TCT A C
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"The plasmids HA-tagged NF2 (a gift from Dr. Y. J. LU, Tongji University, China)",0.9,Accept,Experimental Usage,NF2,Plasmid,,,,,HA,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,Flag-tagged P53 (Addgene; #10838),0.9,Accept,Experimental Usage,P53,Plasmid,,,,,Flag,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"Cell viability was determined by Cell Counting Kit-8 (CCK-8) from Dojindo (Kumamoto, Japan)",0.75,Accept,Experimental Usage,CCK-8,Other,,,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Murine CXCL12 cDNA was subcloned into the lentiviral vector,0.85,Accept,Experimental Usage,CXCL12,Viral,,,Mouse,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,A second packaging vector (FUW-FLG) encoding a fusion of firefly luciferase and enhanced green fluorescent protein,0.85,Accept,Experimental Usage,firefly luciferase-GFP fusion,Viral,,human ubiquitin-C,,,GFP,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,"CRISPR/Cas9 single-vector lentivirus was purchased from GeneChem (Shanghai, China)",0.9,Accept,Experimental Usage,NF1,Viral,,,,,Puromycin,,
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,Construction of pET-Spred1(EVH1) encoding the EVH1 domain of human Spred1 (Ser13–Ser130) preceded by a non-native translation initiating methionine,0.85,Accept,Experimental Usage,Spred1(EVH1),Plasmid,pET,,Human,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,Everolimus (RAD001) inhibits the mTOR and is currently FDA approved for several types of solid tumors,0.8,Accept,Experimental Usage,Everolimus,,,,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,"PD-0325901 (PD-901) inhibits MEK, a component of the MAPK pathway, and is currently in clinical trials",0.8,Accept,Experimental Usage,PD-0325901,,,,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,Point mutations in NF1 isoform-2 were generated by PCR mutagenesis of Addgene plasmid 70423.,0.85,Accept,Experimental Usage,NF1 isoform-2,Plasmid,,,Human,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,"Gateway LR recombination according to the manufacturer's protocol to insert NF1, SPRED1, and RAS entry clones into transient mammalian expression vectors pCAN-FLAG-DEST",0.8,Accept,Experimental Usage,FLAG,Plasmid,,,,,FLAG,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,"Gateway LR recombination according to the manufacturer's protocol to insert NF1, SPRED1, and RAS entry clones into transient mammalian expression vectors pCAN-FLAG-DEST and pCAN-HA-DEST",0.8,Accept,Experimental Usage,HA,Plasmid,,,,,HA,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,the lentiviral attR1-attR2 Gateway destination vector pLIX403 (Addgene 41395) was modified to attR4-attR2 by Gibson assembly,0.85,Accept,Experimental Usage,Tet-inducible,Viral,pLIX403,TRE3G,,,Puromycin,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,Lentiviral particles were then generated by equimolar cotransfection of these NF1 expression vectors with psPAX2 (Addgene 12260),0.8,Accept,Experimental Usage,packaging,Plasmid,psPAX2,,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,Lentiviral particles were then generated by equimolar cotransfection of these NF1 expression vectors with psPAX2 (Addgene 12260) and pMD2.G (Addgene 12259) packaging plasmids,0.8,Accept,Experimental Usage,envelope,Plasmid,pMD2.G,,,,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,DNA was extracted from peripheral blood samples using PureGene Blood Core Kit B (Qiagen),0.85,Accept,Experimental Usage,DNA extraction kit,Other,,,,,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,NGS was performed by oligonucleotide hybridization‐based DNA capture (SureSelect; Agilent),0.8,Accept,Experimental Usage,DNA capture system,Other,,,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"Human RABL6A and RB1 shRNAs in the pLKO.1 lentiviral vector (Open Biosystems, Huntsville, AL, USA)",0.9,Accept,Experimental Usage,RABL6A shRNA,Viral,pLKO.1,,Human,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"Human RABL6A and RB1 shRNAs in the pLKO.1 lentiviral vector (Open Biosystems, Huntsville, AL, USA)",0.9,Accept,Experimental Usage,RB1 shRNA,Viral,pLKO.1,,Human,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"stained using the Senescence β-Galactosidase Staining Kit (Cell Signaling Technology #9860, Danvers, MA, USA)",0.8,Accept,Experimental Usage,β-Galactosidase,,,,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,"shRNAs targeting PTPN11 #5003 and #818 were subcloned into Tet-pLKO-puro vector (Addgene, no. 21915)",0.85,Accept,Experimental Usage,Tet-pLKO-puro,Plasmid,pLKO,,,,Puromycin,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,The human NF1-GRD was amplified using the genomic deoxyribonucleic acid (gDNA) from HEK293T as polymerase chain reaction template and subcloned into TTIGFP-MLUEX vector,0.85,Accept,Experimental Usage,TTIGFP-MLUEX,Plasmid,,Tet-regulated promoter,,,GFP,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,shRNAs targeting PTPN11 #5003 and #818 were subcloned into Tet-pLKO-puro vector,0.9,Accept,Experimental Usage,shPTPN11,Plasmid,pLKO,Tet-regulated,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,shRNAs targeting PTPN11 #5003 and #818 were subcloned into Tet-pLKO-puro vector,0.9,Accept,Experimental Usage,shPTPN11,Plasmid,pLKO,Tet-regulated,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,The human NF1-GRD was amplified using the genomic deoxyribonucleic acid (gDNA) from HEK293T as polymerase chain reaction template and subcloned into TTIGFP-MLUEX vector,0.85,Accept,Experimental Usage,NF1-GRD,Plasmid,TTIGFP-MLUEX,,Human,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,UAS-Nf1-eGFP transgenes were generated using an Nf1 mini-gene (full-length Nf1 cDNA corresponding to the RF isoform with addition of introns 9 and 10).,0.9,Accept,Development,Nf1-eGFP,Plasmid,pUAST-attB,,,,GFP,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,The R1320P mutation was created in a wild-type cDNA using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs).,0.8,Accept,Experimental Usage,Q5 Site-Directed Mutagenesis Kit,,,,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,The Nf1 RNAi line was obtained from the Vienna Drosophila RNAi Center (VDRC #109637),0.85,Accept,Experimental Usage,Nf1 RNAi,Other,,,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,ERK was activated via expression of ERK with the gain-of-function mutation ERK 56 Sem (UAS-rl Sem).,0.85,Accept,Experimental Usage,rl Sem,,,,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635),0.85,Accept,Experimental Usage,nSyb,,,,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635), R57C10 (39171)",0.85,Accept,Experimental Usage,R57C10,,,,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635), R57C10 (39171), 69B (1774), tsh-Gal4 (3040)",0.85,Accept,Experimental Usage,tsh-Gal4,,,,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635), R57C10 (39171), 69B (1774), tsh-Gal4 (3040), and Oct-TyrR-Gal4 (36494).",0.85,Accept,Experimental Usage,Oct-TyrR-Gal4,,,,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,PCB-Gal4 (fatbody-Gal4) was previously generated by Ronald Kühnlein,0.85,Accept,Experimental Usage,PCB-Gal4,,,,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,a conditionally expressed SB transposase enzyme (R26-lsl-SB11),0.85,Accept,Experimental Usage,SB11,Other,,,Mouse,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,a Schwann cell specific Cre-recombinase controlled by the CNP promoter (Cnp-Cre),0.85,Accept,Experimental Usage,Cre,,,CNP,Mouse,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,a concatomer of oncogenic transposons (T2/Onc15),0.85,Accept,Experimental Usage,T2/Onc15,Transposon,,,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,"MPNST predisposing alleles, Cnp-EGFR and conditional Trp53 alleles",0.85,Accept,Experimental Usage,EGFR,,,CNP,Human,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,shRNA GIPZ lentiviral constructs were purchased from Openbiosystems,0.85,Accept,Experimental Usage,shRNA,Viral,GIPZ,,,,Puromycin,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,FOXR2 cDNA (Open Biosystems) was cloned into the Gateway Vector System (Invitrogen) and subcloned into a piggyBac (PB) transposon vector,0.85,Accept,Experimental Usage,FOXR2,Transposon,piggyBac,,,,Puromycin,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,TALENs targeting FOXR2 were designed using TALE-NT and constructed,0.85,Accept,Experimental Usage,FOXR2,Other,,,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,An HPRT TALEN pair served as a control,0.85,Accept,Experimental Usage,HPRT,Other,,,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,QuantiTech Qiagen primers:  KCNMA1  (cat# QT00024157),0.9,Accept,Experimental Usage,KCNMA1,Other,,,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,PRKCE  (cat# QT00016352),0.9,Accept,Experimental Usage,PRKCE,Other,,,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,OPCML  (cat# QT01005361),0.9,Accept,Experimental Usage,OPCML,Other,,,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,GRIK2  (cat# QT00016597),0.9,Accept,Experimental Usage,GRIK2,Other,,,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,CADM2  (cat# QT00048888),0.9,Accept,Experimental Usage,CADM2,Other,,,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,CREB5  (cat# QT00054488),0.9,Accept,Experimental Usage,CREB5,Other,,,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,CAMK1D  (cat# QT00036344),0.9,Accept,Experimental Usage,CAMK1D,Other,,,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,ITGB8  (cat# QT00038507),0.9,Accept,Experimental Usage,ITGB8,Other,,,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,"Genomic DNA from tumor and normal samples were fragmented and used for Illumina TruSeq library construction (Illumina, San Diego, CA) according to the manufacturer's instructions.",0.85,Accept,Experimental Usage,TruSeq library construction kit,Other,,,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,"DNA was purified using Agencourt AMPure XP beads (Beckman Coulter, IN) in a ratio of 1.0–0.9 of PCR product to beads.",0.8,Accept,Experimental Usage,AMPure XP beads,Other,,,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,"5 µl of End Repair Enzyme Mix (cat# E6050, NEB, Ipswich, MA). The 100 µl end-repair mixture was incubated at 20°C for 30 min",0.9,Accept,Experimental Usage,End Repair Enzyme Mix,Other,,,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,"42 µl of end-repaired DNA was mixed with 5 µl of 10 X dA Tailing Reaction Buffer and 3 µl of Klenow (exo-)(cat# E6053, NEB, Ipswich, MA).",0.9,Accept,Experimental Usage,Klenow (exo-),Other,,,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,"10 µl of 5 X Ligation buffer and 5 µl of Quick T4 DNA ligase (cat# E6056, NEB, Ipswich, MA). The ligation mixture was incubated at 20°C for 15 min",0.9,Accept,Experimental Usage,Quick T4 DNA ligase,Other,,,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,"Exonic regions were captured in solution using the Agilent SureSelect v.4 kit (Agilent, Santa Clara, CA).",0.85,Accept,Experimental Usage,SureSelect v.4,Other,,,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,"cfDNA from each of the plasma samples was purified using a BioChain cfDNA Extraction Kit (BioChain, cat #K5011610) using the manufacturer's recommended protocol.",0.9,Accept,Experimental Usage,cfDNA Extraction Kit,Other,,,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,Cell-free DNA was extracted using the QIAGEN circulating nucleic acid kit (Catalog# 55114).,0.9,Accept,Experimental Usage,circulating nucleic acid kit,Other,,,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC)",0.9,Accept,Development,anti-HER1 CAR 806,Viral,,,Human,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC)",0.9,Accept,Development,anti-HER1 CAR E2,Viral,,,Human,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC)",0.9,Accept,Development,anti-HER1 CAR NEC,Viral,,,Human,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,Small interfering RNA (siRNA) targeting NF1 (s221793),0.9,Accept,Experimental Usage,NF1,Other,,,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,siRNA targeting...AHR (s1200),0.9,Accept,Experimental Usage,AHR,Other,,,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,"bevacizumab 5 mg/kg b.w., Avastin® 100 mg/25 ml, Roche, Basel, Switzerland",0.85,Accept,Experimental Usage,bevacizumab,,,,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,"murine bevacizumab 5 mg/kg b.w. (B20-4.1.1, 100 mg/25 ml, Roche, Basel, Switzerland)",0.85,Accept,Experimental Usage,bevacizumab,,,,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,"IV gadolinium contrast injection (0.1 ml/kg, Gadovist, Bayer Inc.)",0.8,Accept,Experimental Usage,gadolinium contrast,,,,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,"IV microbubble administration (0.02 ml/kg, Definity, Lantheus Medical Imaging, USA)",0.8,Accept,Experimental Usage,microbubbles,,,,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,U6-gRNA vectors were produced as previously described and introduced into iHSCs that are proficient for NF1,0.85,Accept,Experimental Usage,gRNA,Plasmid,,U6,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,One million cells were electroporated (1 pulse of 1400V for 30 ms) with 2 µg Flag-hCas9,0.85,Accept,Experimental Usage,Cas9,,,,Human,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,co-transposition was performed using 500 ng of the piggyBac (PB) transposon PB-CAGG-Luciferase-IRES-GFP-PGK-PuroR,0.9,Accept,Experimental Usage,Luciferase-IRES-GFP,Transposon,,CAGG,,,Puromycin,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,500 ng of CMV-PB7 transposase,0.85,Accept,Experimental Usage,PB7 transposase,,,CMV,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,MEK inhibitor PD0325901...Ten mice were treated with ATRA (15 mg/kg) or PD0325901 (10 mg/kg),0.85,Accept,Experimental Usage,PD0325901,,,,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,all-trans retinoic acid (ATRA)...Ten mice were treated with ATRA (15 mg/kg) or PD0325901 (10 mg/kg),0.85,Accept,Experimental Usage,ATRA,,,,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,"Reverse transcription was carried out using SYBR premix EX Taq (Takara, Japan)",0.85,Accept,Experimental Usage,SYBR premix EX Taq,,,,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,and SYBR Premix Ex Taq II (Takara) was used for qPCR,0.85,Accept,Experimental Usage,SYBR Premix Ex Taq II,,,,,,,,
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,"Sample RNA was processed in triplicate with serial dilutions of Human Universal Reference RNA (Stratagene, La Jolla, CA, USA)",0.75,Accept,Experimental Usage,Human Universal Reference RNA,,,,Human,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,"trastuzumab (25 mg/kg in 0.25 ml normal saline i.p., Genentech, South San Francisco, CA)",0.85,Accept,Experimental Usage,trastuzumab,,,,,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,"erlotinib (50 mg/kg, Genentech, South San Francisco, CA), five days a week",0.85,Accept,Experimental Usage,erlotinib,,,,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"AZD2014 (provided by AstraZeneca; Wilmington, DE)",0.85,Accept,Experimental Usage,AZD2014,,,,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"FRAX597 (generously given by Dr. Joseph Kissil, The Scripps Research Institute, Jupiter, FL)",0.8,Accept,Experimental Usage,FRAX597,,,,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"6,091 shRNAs, cloned into the pLKO-puromycin system",0.9,Accept,Experimental Usage,shRNA,Plasmid,pLKO,,,,Puromycin,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,pLKO-puro-based shRNAs targeting human SGK1 (TRCN0000194957),0.9,Accept,Experimental Usage,SGK1,Plasmid,pLKO,,,,Puromycin,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,human PAK1 (TRCN0000197238),0.9,Accept,Experimental Usage,PAK1,Plasmid,pLKO,,,,Puromycin,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,human RHEB (TRCN0000010424),0.9,Accept,Experimental Usage,RHEB,Plasmid,pLKO,,,,Puromycin,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,transfected using program U-023 with lenti-CRISPR-NF2_sg1 expressing a single guide RNA targeting human NF2 exon 8,0.9,Accept,Experimental Usage,NF2,Viral,lenti-CRISPR,,,,Puromycin,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,All PCR reactions were performed using an ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems) and either the TaqMan ® PCR Core REAGENTS Kit,0.9,Accept,Experimental Usage,TaqMan PCR Core REAGENTS Kit,Other,,,,,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,or the SYBR ® Green PCR Core Reagents kit (Perkin-Elmer Applied Biosystems),0.9,Accept,Experimental Usage,SYBR Green PCR Core Reagents kit,Other,,,,,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,"20 units of RNasin RNase inhibitor (Promega, Madison, WI)",0.85,Accept,Experimental Usage,RNasin RNase inhibitor,Other,,,,,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,"100 units of Superscript II RNase H-reverse transcriptase (Invitrogen, Cergy Pontoise, France)",0.9,Accept,Experimental Usage,Superscript II RNase H-reverse transcriptase,Other,,,,,,,
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,Nuclear and non-nuclear fractions were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents following manufacturer's instructions (Thermo Fisher Scientific).,0.85,Accept,Experimental Usage,NE-PER Nuclear and Cytoplasmic Extraction Reagents,,,,,,,,
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,plated in 0.34% low melting temperature agarose (FMC Bioproducts) in complete medium at 2×10 4 (Meso-33 cells) or 1.2×10 4 (FC-1801 cells) per well in 24-well Ultra Low Cluster Plates (Costar).,0.75,Accept,Experimental Usage,Ultra Low Cluster Plates,,,,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,subcloned as a Bgl II/Xho I fragment into the retroviral expression vector pBMN-I-GFP,0.9,Accept,Experimental Usage,GFP,Viral,,,,,GFP,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,A GST-PID (Pak1 amino acids 83–149) or Gst-PID L107F cDNA was subcloned,0.9,Accept,Experimental Usage,GST-PID,Plasmid,,,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,A GST-PID (Pak1 amino acids 83–149) or Gst-PID L107F cDNA was subcloned,0.9,Accept,Experimental Usage,Gst-PID L107F,Plasmid,,,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,"RNAi was performed using ON-TARGETplus Non-targeting Pool (#D-001810–10-05, Dharmacon)",0.85,Accept,Experimental Usage,Non-targeting control,Other,,,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,"SMARTPool ON-TARGETplus Human PTPN11 siRNA (#L-003947–00-0005, Dharmacon) to knockdown (KD) the expression of non-targeting control (NTC) and SHP2",0.9,Accept,Experimental Usage,PTPN11,Other,,,Human,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,"we developed the I2HCP panel, a custom bait library covering 122 hereditary cancer genes",0.9,Accept,Development,I2HCP panel,Other,,,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,"We used Agilent eArray to design our SureSelect bait library V1 (Agilent, California, USA), covering 106 genes",0.85,Accept,Experimental Usage,SureSelect bait library V1,Other,,,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,The bait library V2 included 122 genes responsible for most of the cancer predisposition syndromes,0.85,Accept,Experimental Usage,SureSelect bait library V2,Other,,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"We infected secondary Nf1 neurofibroma spheres or fl/fl;DhhCre Stat3 DRG/neurofibroma spheres with shRNAs and non-target control (Sigma, St Louis, MO, USA)",0.85,Accept,Experimental Usage,shRNAs,Viral,,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"β-catenin overexpression lentivirus ΔN90 (Addgene, Cambridge MA)",0.9,Accept,Experimental Usage,β-catenin ΔN90,Viral,,,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,checked for loss of heterozygosity in tumor DNA at markers D22S193 (centromeric to NF2),0.85,Accept,Experimental Usage,D22S193,Other,,,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,"at markers D22S193 (centromeric to NF2), NF2 TET and D22S929 (intragenic)",0.85,Accept,Experimental Usage,NF2 TET,Other,,,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,"NF2 TET and D22S929 (intragenic), and D22S268 and D22S430",0.85,Accept,Experimental Usage,D22S929,Other,,,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,"D22S929 (intragenic), and D22S268 and D22S430 (telomeric to NF2)",0.85,Accept,Experimental Usage,D22S268,Other,,,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,and D22S268 and D22S430 (telomeric to NF2),0.85,Accept,Experimental Usage,D22S430,Other,,,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,"PCR products were then digested using the endonuclease BstUI in 30 μl volumes according to the manufacturer's specifications (New England Biolabs, Beverly, MA)",0.9,Accept,Experimental Usage,BstUI,Other,,,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,"1 μl of 10X buffer, and 0.25 U of Taq polymerase (Qiagen, Valencia, CA)",0.9,Accept,Experimental Usage,Taq polymerase,Other,,,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,"The incorporated EdU were stained on top of BrdU staining with Click-iT™ EdU Cell Proliferation Kit for Imaging (ThemoFisher, Cat# C10337)",0.8,Accept,Experimental Usage,EdU,,,,,,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,Lineage-marker-negative (Lin-) cells were purified through a 0.3-in StemSep negative selection column as per the manufacturer's instructions,0.75,Accept,Experimental Usage,StemSep,Other,,,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"Rapamycin (LC Laboratories, catalog number R-5000; Supplementary Fig. S1A)",0.75,Accept,Experimental Usage,Rapamycin,,,,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"NVP-BEZ235 (LC Laboratories, catalog number 915019-65-7; Supplementary Fig. S1B)",0.75,Accept,Experimental Usage,NVP-BEZ235,,,,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"and LY294002 (Calbiochem, San Diego CA) were purchased from commercial sources",0.75,Accept,Experimental Usage,LY294002,,,,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,the HCN channel agonist lamotrigine rescued the electrophysiological and cognitive deficits,0.8,Accept,Experimental Usage,lamotrigine,,,,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.2% biocytin was included in the intracellular pipette solution for later morphological identification,0.75,Accept,Experimental Usage,biocytin,,,,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"Mirdametinib (also known as PD0325901) has the chemical structure of N-[(2R)-2,3 dihydroxypropoxyl]-3,4-difluro-2-[(2-fluoro-4-iodophenyl) amino] benzamide",0.95,Accept,Experimental Usage,mirdametinib,,,,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,Cell lines were infected with NucLight red lentivirus and stably selected in puromycin,0.85,Accept,Experimental Usage,NucLight red,Viral,,,,,Puromycin,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,The human lncRNA WT1-AS were cloned into plasmid cloning DNA (pcDNA) vector,0.8,Accept,Experimental Usage,WT1-AS,Plasmid,pcDNA,,Human,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,Total cellular RNA was extracted from glioma tissues and cultured cells using the commercially procured TRIzol reagent (Invitrogen),0.75,Accept,Experimental Usage,RNA extraction reagent,Other,,,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,RNA was reverse transcribed in to complementary DNA (cDNA) using the commercial Transcriptor First strand cDNA synthesis kit (Roche Diagnostics),0.8,Accept,Experimental Usage,cDNA synthesis,Other,,,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,"The WT1-AS sequence including the putative binding sites of miR-494-3p was subcloned and then inserted into the pmirGLO vector (Promega, Madison, Wisconsin)",0.8,Accept,Experimental Usage,WT1-AS,Plasmid,pmirGLO,,Human,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,co-transfected with the packaging plasmids psPAX (Addgene #12260),0.9,Accept,Experimental Usage,psPAX,Plasmid,,,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,"and pMD2.G (Addgene, #12259)",0.9,Accept,Experimental Usage,pMD2.G,Plasmid,,,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,injected with Tol2(UAS:eGFP-KRAS G12D) plasmid,0.9,Accept,Experimental Usage,UAS:eGFP-KRAS G12D,Transposon,Tol2,UAS,,,eGFP,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,"Cytotoxic efficacy of the non-adherent spleen cells was assessed by adding them as effector cells to PNF-derived Schwann cells as target cells at a ratio of 1∶10 for 4 h using the CytoTox 96 Non-Radioactive Cytotoxicity assay (Promega, Fitchburg, WI)",0.8,Accept,Experimental Usage,CytoTox 96,,,,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,"Sequencing libraries were prepared using TruSeq Stranded Total RNA Sample Preparation kit (Illumina, San Diego, CA)",0.8,Accept,Experimental Usage,TruSeq Stranded Total RNA,,,,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,"mRNA was reverse transcribed using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsabd, CA)",0.8,Accept,Experimental Usage,SuperScript III,,,,,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,RNA from primary astrocytes was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol,0.8,Accept,Experimental Usage,RNA isolation kit,,,,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,"Genomic DNA (gDNA) was extracted from both frozen tumour and blood tissues using the DNeasy mini kit (Qiagen, Valencia, CA, USA)",0.85,Accept,Experimental Usage,DNeasy mini kit,Other,,,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,"Standard whole genome library prep was done using the NEBNext DNA Library Prep Reagent Set for Illumina (New England BioLabs Inc., Ipswich, MA, USA)",0.85,Accept,Experimental Usage,NEBNext DNA Library Prep Reagent Set,Other,,,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,Accurate quantification for sequencing applications was determined using the qPCR-based KAPA Biosystems Library Quantification Kit,0.85,Accept,Experimental Usage,KAPA Library Quantification Kit,Other,,,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,"SNP array sample prep was done using the HumanOmni2.5–8 (Illumina, Inc., San Diego, CA, USA)",0.85,Accept,Experimental Usage,HumanOmni2.5-8,Other,,,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,"Total RNA containing both mRNA as well as microRNA fractions was extracted from the tissues using the miRNeasy mini kit (Qiagen, Valencia, CA, USA)",0.85,Accept,Experimental Usage,miRNeasy mini kit,Other,,,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,Poly-adenylated RNAs were isolated using NEBNext Magnetic Oligo d(T)25 Beads,0.85,Accept,Experimental Usage,NEBNext Magnetic Oligo d(T)25 Beads,Other,,,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,"The NEBNext mRNA Library Prep Reagent Set for Illumina (New England BioLabs Inc., Ipswich, MA, USA) was then used to prepare individually bar-coded",0.85,Accept,Experimental Usage,NEBNext mRNA Library Prep Reagent Set,Other,,,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,"Paired-end sequencing (25 million, 50-bp, paired-end reads) was performed using a 200 Cycle TruSeq SBS HS v4 Kit",0.85,Accept,Experimental Usage,TruSeq SBS HS v4 Kit,Other,,,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,synthetic gene (GeneArt) encoding the human full-length NF1 (synNF1) was cloned into the pFastBacHta (Life Technology) vector,0.85,Accept,Experimental Usage,NF1,Plasmid,pFastBacHta,,Human,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,synthetic gene (GeneArt) encoding the human full-length NF1 (synNF1),0.9,Accept,Experimental Usage,NF1,,,,Human,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,full-length human neurofibromin with C-terminal eGFP tag (synNF1eGFP),0.9,Accept,Experimental Usage,NF1-eGFP,,,,Human,,GFP,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,"SynNF1 was transduced into fibroblasts using the transduction reagent EndoPorter (GeneTools, LLC)",0.8,Accept,Experimental Usage,EndoPorter,Other,,,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,"transfected with 4 siRNAs (FlexiTube, Qiagen, Hilden; Supplementary Table 2) designed for silencing the NF1 message",0.85,Accept,Experimental Usage,NF1 siRNA,Other,,,Human,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,As a control the Allstar Negative Control siRNA (Qiagen) was used,0.8,Accept,Experimental Usage,Control siRNA,Other,,,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,using the Lipofectamine RNAiMAX transfection reagent (Life Technologies),0.8,Accept,Experimental Usage,Lipofectamine RNAiMAX,Other,,,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,"RNAs were isolated using RNeasy mini kit (QIAGEN, Valencia, CA)",0.8,Accept,Experimental Usage,RNA extraction kit,Other,,,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,PEGylated interferon alpha-2b was purchased at the Cincinnati Children's Hospital (National Drug Code 00085132302) pharmacy,0.8,Accept,Experimental Usage,interferon alpha-2b,Other,,,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,cfDNA was extracted from 2 to 8 mL of plasma using the QIAamp Circulating Nucleic Acid kit (Qiagen),0.85,Accept,Experimental Usage,QIAamp Circulating Nucleic Acid kit,Other,,,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,Extracted DNA concentration was measured using the Qubit dsDNA High-Sensitivity Assay kit (Thermo-Fisher),0.85,Accept,Experimental Usage,Qubit dsDNA High-Sensitivity Assay kit,Other,,,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,cfDNA sequencing libraries were constructed from 10 to 60 ng of isolated DNA using the KAPA HyperPrep kit (Roche),0.85,Accept,Experimental Usage,KAPA HyperPrep kit,Other,,,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,cfDNA sequencing libraries were constructed from 10 to 60 ng of isolated DNA using the KAPA HyperPrep kit (Roche) and xGen UDI-UMI Adapters (IDT),0.85,Accept,Experimental Usage,xGen UDI-UMI Adapters,Other,,,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,Tissue genomic profiling was performed by Clinical Laboratory Improvement Amendments–certified molecular laboratories using TruSight Oncology 500 (Illumina),0.85,Accept,Experimental Usage,TruSight Oncology 500,Other,,,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,EdU detection was performed on 14 μm-thick cryosections using the Click-IT Plus EdU Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientific),0.85,Accept,Experimental Usage,EdU,,,,,,Alexa Fluor 488,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,We isolated total RNA from frozen tissue and cells using the RNeasy kit (Qiagen),0.8,Accept,Experimental Usage,RNA isolation reagent,Other,,,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,we infected MPNST cells at 70–90% confluence with lentiviral particles containing shRNAs targeting SOX9 (Open Biosystems; TRC library),0.9,Accept,Experimental Usage,shSOX9,Viral,,,,,Puromycin,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,lentiviral particles containing shRNAs targeting SOX9 (Open Biosystems; TRC library) or GFP (Addgene),0.85,Accept,Experimental Usage,GFP,Viral,,,,,Puromycin,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,We conducted MTS assays for viable cell number on days 3–7 post-infection using the CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega),0.8,Accept,Experimental Usage,MTS assay reagent,Other,,,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,"we fixed cells in 4% paraformaldehyde for the detection of nuclear DNA fragmentation with the DeadEnd Fluorometric TUNEL System (Promega; Madison, WI)",0.8,Accept,Experimental Usage,TUNEL assay reagent,Other,,,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,"The vector pTYcPPT, containing the elongation factor 1 alpha promoter, was used to separately clone hTERT and mCdk4",0.85,Accept,Experimental Usage,hTERT and mCdk4,Viral,pTYcPPT,EF1α,Human and Mouse,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,full length human telomerase reverse transcriptase cDNA,0.9,Accept,Experimental Usage,hTERT,Viral,,,Human,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,murine Cdk4 full-length cDNA,0.9,Accept,Experimental Usage,mCdk4,Viral,,,Mouse,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,"Oligonucleotide pairs were annealed and cloned into the transfer plasmid lentiCRISPRv2 (Addgene, Watertown, MA, USA, #52961)",0.9,Accept,Experimental Usage,CRISPR-Cas9,Plasmid,lentiCRISPRv2,,,,Puromycin,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,NF1-GRD sequence was introduced in Nf1−/− MEFs using the pMSCV-GRD vector,0.9,Accept,Experimental Usage,NF1-GRD,Viral,pMSCV,,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,pBABE vectors were used for expression of constitutively active (CA: S217E/S221E) and dominant negative (DN: S217A) MEK1 and hyperactive RAS (G12D mutant),0.9,Accept,Experimental Usage,pBABE vectors,Viral,pBABE,,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,"The NAD+/NADH ratio was measured using the NAD+/NADH colorimetric assay kit (Abcam, Waltham, MA, USA)",0.8,Accept,Experimental Usage,NAD+/NADH assay,,,,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,2 µg of total RNA was used to synthesize cDNA with the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific),0.8,Accept,Experimental Usage,SuperScript III,,,,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,Measurements of mitochondrial ROS were performed by MitoSOX (Thermo Fisher Scientific) staining,0.8,Accept,Experimental Usage,MitoSOX,,,,,,,,
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,Four standard 10-μm-thick sections were stained with Hematoxylin & Eosin for each specimen,0.85,Accept,Experimental Usage,Hematoxylin & Eosin,Other,,,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,"siRNA pool targeting KIF15, KIF23, or a non-targeting control (NTC; siGENOME SMARTpool, Dharmacon)",0.9,Accept,Experimental Usage,KIF15/KIF23 siRNA,Other,,,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,pX330-U6-Chimeric_BB-CBh-HSpCas0 (Addgene),0.9,Accept,Experimental Usage,Cas9,Plasmid,pX330,U6,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,pRGS2 surrogate reporter (Labomics),0.9,Accept,Experimental Usage,RGS2,Plasmid,,,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,"ispinesib (Selleckchem) or ARRY-520 (MedChemExpress), which selectively inhibit KIF11",0.8,Accept,Experimental Usage,ispinesib,,,,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,"ispinesib (Selleckchem) or ARRY-520 (MedChemExpress), which selectively inhibit KIF11",0.8,Accept,Experimental Usage,ARRY-520,,,,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,"The human cDNA encoding the full-length Merlin isoform 1 was subcloned into the pET32a vector (EMD Biosciences, Inc), with a 6XHis plus thioredoxin tag",0.85,Accept,Experimental Usage,Merlin isoform 1,Plasmid,pET32a,,Human,,6XHis plus thioredoxin tag,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,The Merlin(S518D) and Merlin(S518E) mutants were generated with the QuikChange II site-directed mutagenesis kit (Agilent Technologies),0.8,Accept,Experimental Usage,Merlin(S518D) and Merlin(S518E) mutants,Other,,,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,The supernatant ran through a 5 ml HiTrap Chelating Sepharose™ High Performance (GE healthcare) and washed extensively,0.75,Accept,Experimental Usage,HiTrap Chelating Sepharose™ High Performance,Other,,,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Further purification followed by gel filtration chromatography using a Superdex 200 10/300 GL column (GE Healthcare),0.75,Accept,Experimental Usage,Superdex 200 10/300 GL column,Other,,,,,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,Cre recombinase was targeted to the mouse leptomeninges by direct injection of 3 µL (1 × 10 8 plaque‐forming units) of adCre suspension,0.85,Accept,Experimental Usage,Cre,Viral,,,,,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,"all animals were intraperitoneally injected (1) a MR contrast agent, Gd-DTPA (Magnevist ®, Schering, Leverkusen, Germany) at a dose of 0.8 mL/kg",0.75,Accept,Experimental Usage,Gd-DTPA,,,,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,Tumor genotyping was performed with the Human Mapping 100K Set platform ( Affymetrix ),0.8,Accept,Experimental Usage,Human Mapping 100K Set,Other,,,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,gene-expression data were obtained using GeneChip Human Genome U133 Plus 2.0 Arrays ( Affymetrix ),0.8,Accept,Experimental Usage,GeneChip Human Genome U133 Plus 2.0 Arrays,Other,,,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,"For MEKi treatment, 1 μg/mL PD0325901 (Selleckchem, S1036) was added to cell culture for 72 hours.",0.85,Accept,Experimental Usage,PD0325901,,,,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,Two predesigned siRNAs against human NF1 were purchased from MilliporeSigma (SASI_Hs01_00129008 and SASI_Hs01_00129006).,0.9,Accept,Experimental Usage,NF1,Other,,,Human,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,"Mouse tissues were collected and lysed with the CNMCS Compartmental Protein Extraction Kit (Millipore, 2145)...",0.8,Accept,Experimental Usage,CNMCS Compartmental Protein Extraction Kit,,,,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Full-length murine PDE4A1 or catalytically inactive PDE4A1-H229Q was cloned into a lentiviral packaging vector that also encodes mCherry fluorescent protein,0.9,Accept,Development,PDE4A1,Viral,,,Mouse,,mCherry,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Full-length murine PDE4A1 or catalytically inactive PDE4A1-H229Q was cloned into a lentiviral packaging vector that also encodes mCherry fluorescent protein,0.9,Accept,Development,PDE4A1-H229Q,Viral,,,Mouse,,mCherry,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,A second packaging vector (FUW-FLG) encoding a fusion of firefly luciferase and enhanced green fluorescent protein driven by the human ubiquitin C promoter,0.85,Accept,Experimental Usage,firefly luciferase-eGFP fusion,Viral,FUW,human ubiquitin C,,,eGFP,,
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,GL261-luc cells were generated by infection of lentivirus carrying luciferase as described.,0.75,Accept,Experimental Usage,luciferase,Viral,lentivirus,,Unknown,,,,
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,"Conditional gene expression, CRISPR-CAS9, and shRNA-mediated knockdown were used to perform gain/loss-of-function experiments",0.85,Accept,Experimental Usage,CAS9,Other,,,,,,,
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,"CRISPR-CAS9, and shRNA-mediated knockdown were used to perform gain/loss-of-function experiments to explore the effect of reconstituting the GTPase-activating protein-related domain of NF1",0.85,Accept,Experimental Usage,shRNA,Other,,,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,"selumetinib (Tocris, catalog 6815), ogerin (Tocris, catalog 5722)",0.9,Accept,Experimental Usage,selumetinib,,,,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,"selumetinib (Tocris, catalog 6815), ogerin (Tocris, catalog 5722)",0.9,Accept,Experimental Usage,ogerin,,,,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,"GANT61 (Tocris, catalog 3191), LGK-974 (Selleckchem, catalog S7143)",0.9,Accept,Experimental Usage,GANT61,,,,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,"GANT61 (Tocris, catalog 3191), LGK-974 (Selleckchem, catalog S7143)",0.9,Accept,Experimental Usage,LGK-974,,,,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,"PAM71 (MedChemExpress, catalog HY-134494), 8-(4-Chlorophenylthio)adenosine",0.9,Accept,Experimental Usage,PAM71,,,,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,"8-(4-Chlorophenylthio)adenosine 3′,5′-cyclic monophosphate (8CPT cAMP) (Abcam, catalog ab120424)",0.9,Accept,Experimental Usage,8CPT cAMP,,,,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,"Forskolin (MilliporeSigma, catalog F6886). They were prepared as indicated by the manufacturers",0.9,Accept,Experimental Usage,Forskolin,,,,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"Cre recombinase expressing adenovirus (Ad5CMVCre-GFP High Titer, University of Iowa Viral Vector Core)",0.85,Accept,Experimental Usage,Cre,Viral,,CMV,,,GFP,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,DNA was purified using the Qiagen DNeasy Extraction kit and 0.5 µg was subjected to bisulfite treatment,0.85,Accept,Experimental Usage,DNA extraction reagent,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,"0.5 µg was subjected to bisulfite treatment (Qiagen, EpiTect plus)",0.85,Accept,Experimental Usage,Bisulfite treatment reagent,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,Libraries were constructed from > 200 ng starting genomic DNA using the Agilent SureSelect Human All Exon V5 + UTRs kit,0.85,Accept,Experimental Usage,Exome capture reagent,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,Genomic DNA (0.5–1 µg) libraries were generated using the Illumina TruSeq PCR-free DNA library preparation kit,0.85,Accept,Experimental Usage,Library preparation reagent,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,"Tumor RNA libraries were prepared from 200 ng of RNA and the Illumina TruSeq mStranded Total RNA (N = 18, RIN > 8)",0.85,Accept,Experimental Usage,RNA library preparation reagent,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,"Illumina TruSeq mStranded Total RNA (N = 18, RIN > 8) and Ribo-Zero Gold (N = 6, RIN < 8) kits",0.85,Accept,Experimental Usage,RNA depletion reagent,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,"To validate fusions, purified RNAs were reverse-transcribed using SuperScript VILO kit",0.85,Accept,Experimental Usage,Reverse transcription reagent,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,PCR products were purified using the Qiagen MinElute PCR purification kit and run on a 1.2% agarose gel,0.85,Accept,Experimental Usage,PCR purification reagent,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,Library preparation for NGS was accomplished using the HaloPlex PCR target enrichment system (Agilent Technologies Inc.),0.85,Accept,Experimental Usage,Target enrichment reagent,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,"Sequencing was performed using MiSeq reagent kit version 2, 300 cycles, on the MiSeq instrument",0.85,Accept,Experimental Usage,Sequencing reagent,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,"Loss of heterozygosity (LOH) in 22q was investigated using microsatellites D22S420, D22S539, D22S1174, D22S315, D22S1154, D22S1163, D22S280, D22S277, D22S283, D22S423, D22S274, and D22S1169 from the ABI PRISM Linkage Mapping set version 2.5",0.85,Accept,Experimental Usage,Microsatellite markers,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,"SMARCB1, NF2 and 22q11 MLPA test kits (MRC-Holland, P044_B1, P258_C1 and P324_A2) were used",0.85,Accept,Experimental Usage,MLPA probe set,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,"SMARCB1, NF2 and 22q11 MLPA test kits (MRC-Holland, P044_B1, P258_C1 and P324_A2) were used",0.85,Accept,Experimental Usage,MLPA probe set,Other,,,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,"SMARCB1, NF2 and 22q11 MLPA test kits (MRC-Holland, P044_B1, P258_C1 and P324_A2) were used",0.85,Accept,Experimental Usage,MLPA probe set,Other,,,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,"Timed-pregnant FMPrC dams (gestational day 14–16) underwent oral gavage with 1mg tamoxifen (Sigma-Aldrich, St. Louis, MO)",0.8,Accept,Experimental Usage,tamoxifen,,,,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,"1mg tamoxifen (Sigma-Aldrich, St. Louis, MO) and 1 mg progesterone (Sigma-Aldrich, St. Louis, MO)",0.8,Accept,Experimental Usage,progesterone,,,,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,"followed by either Alexa-Fluor-tagged secondary antibodies (Invitrogen, Grand Island, NY) and DAPI counterstaining",0.8,Accept,Experimental Usage,DAPI,,,,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,or biotinylated secondary antibodies and Vectastain Elite ABC development,0.8,Accept,Experimental Usage,Vectastain Elite ABC,,,,,,,,
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,"Ketotifen fumarate was purchased from Sigma-Aldrich. In the prevention and intervention therapeutic studies, ketotifen 1 mg/mL was prepared in ddH2O and administered via oral gavage at 10 mg/kg once daily",0.85,Accept,Experimental Usage,Ketotifen fumarate,,,,,,,,
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,"To determine if ketotifen had an in vivo effect on mast cell infiltration and degranulation, four-month old Nf1 mice were administered subcutaneous Kit Ligand as previously described",0.8,Accept,Experimental Usage,Kit Ligand,,,,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,"Lentiviral transfer plasmid plus packaging plasmids psPAX2 (gift from Didier Trono, Addgene Plasmid #12260, RRID:Addgene_12260) and pCMV-VSV-G",0.95,Accept,Experimental Usage,psPAX2,Plasmid,psPAX2,,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,"pCMV-VSV-G (gift from Bob Weinberg, Addgene Plasmid #8454, RRID:Addgene_8454) were cotransfected intro HEK-293T cells",0.95,Accept,Experimental Usage,VSV-G,Plasmid,pCMV-VSV-G,CMV,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,A doxycycline-inducible pooled human epigenome-focused lentiviral shRNA plasmid library in the LT3GEPIR mir-E backbone,0.85,Accept,Experimental Usage,shRNA library,Viral,LT3GEPIR mir-E,,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,"Control (sh Ren.713), DNMT1, DNMT3A, and DNMT3B shRNAs were cloned into Tet-ON all-in-one plasmids LT3GEPIR (gift from Johannes Zuber, RRID:Addgene_111177)",0.95,Accept,Experimental Usage,shRNA,Plasmid,LT3GEPIR,,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,Control and SUZ12 sgRNA targeting the VEFS functional domain were cloned into pL-CRISPR.EFS.Blast (plasmid was generated by replacing tagRFP in Addgene Plasmid #57819),0.85,Accept,Experimental Usage,sgRNA,Plasmid,pL-CRISPR.EFS.Blast,EFS,,,Blasticidin,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,"Human SUZ12 cDNA was cloned into pLV-EF1α-IRES-Puro (gift from Tobias Meyer, RRID:Addgene_85132)",0.95,Accept,Experimental Usage,SUZ12,Plasmid,pLV-EF1α-IRES-Puro,EF1α,Human,,Puromycin,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,"...screen a panel of 1912 small molecules (the MIPE 4.0 library [17]) against immortalized NF1 −/−, NF1 +/−, and NF1 +/+ cell lines...",0.8,Accept,Experimental Usage,MIPE 4.0,Other,,,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,CellTiter-Glo 3D Reagent Promega CAT#G968B,0.8,Accept,Experimental Usage,ATP detection reagent,,,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"DNA and RNA were isolated from cell lines, human samples, or mouse allografts using the All-Prep Universal Kit (#80224, QIAGEN)",0.85,Accept,Experimental Usage,All-Prep Universal Kit,Other,,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"Genomic DNA from human tumors were processed for methylation analysis using the Illumina Methylation EPIC Beadchip (#WG-317-1003, Illumina)",0.9,Accept,Experimental Usage,Illumina Methylation EPIC Beadchip,Other,,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"Sequencing libraries were prepared using the Kapa Hyper Prep Kit (#07962312001, Roche)",0.85,Accept,Experimental Usage,Kapa Hyper Prep Kit,Other,,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,exome capture was performed using the Nimblegen SeqCap EZ Human Exome Kit v3.0 (Roche),0.85,Accept,Experimental Usage,Nimblegen SeqCap EZ Human Exome Kit,Other,,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"Library preparation was performed using the TruSeq RNA Library Prep Kit v2 (#RS-122-2001, Illumina)",0.85,Accept,Experimental Usage,TruSeq RNA Library Prep Kit v2,Other,,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,Single-nuclei or single-cell RNA sequencing was performed using the Chromium Single Cell 3′ Library & Gel Bead Kit v3.1 on a 10× Chromium controller,0.85,Accept,Experimental Usage,Chromium Single Cell 3′ Library & Gel Bead Kit v3.1,Other,,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"Viability assays were carried out with the CellTiter 96 Non-Radioactive Cell Proliferation Assay (#G410, Promega)",0.85,Accept,Experimental Usage,CellTiter 96 Non-Radioactive Cell Proliferation Assay,Other,,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"RNA was extracted from cell lines using the RNeasy Mini Kit (#74106, QIAGEN)",0.85,Accept,Experimental Usage,RNeasy Mini Kit,Other,,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"cDNA was synthesized from RNA using iScript cDNA Synthesis kit (#1708891, Bio-Rad)",0.85,Accept,Experimental Usage,iScript cDNA Synthesis kit,Other,,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"Real-time QPCR was performed using PowerUp SYBR Green Master Mix (#A25918, Thermo Fisher Scientific)",0.85,Accept,Experimental Usage,PowerUp SYBR Green Master Mix,Other,,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"Lentivirus containing pMH0001 (UCOE-SFFV-dCas9-BFP-KRAB, #85969, Addgene) was produced",0.9,Accept,Experimental Usage,dCas9-BFP-KRAB,Plasmid,pMH0001,SFFV,,,BFP,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"Subsequent gene specific knockdowns were achieved by individually cloning single-guide RNA (sgRNA) protospacer sequences into the pCRISPRia-v2 vector (#84832, Addgene)",0.9,Accept,Experimental Usage,sgRNA,Plasmid,pCRISPRia-v2,,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,ALDH1A1 (TRCN0000026415)—5′-GCCAAATCATTCCTTGGAATTT-3′,0.9,Accept,Experimental Usage,ALDH1A1,Plasmid,pLKO.1-puro,,,,Puromycin,,5′-GCCAAATCATTCCTTGGAATTT-3′
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,TAZ (TRCN0000307197)—5′-CGGACTTCATTCAAGAGGAAT-3′,0.9,Accept,Experimental Usage,TAZ,Plasmid,pLKO.1-puro,,,,Puromycin,,5′-CGGACTTCATTCAAGAGGAAT-3′
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,YAP (TRCN0000107266)—5′-GCCACCAAGCTAGATAAAGAA-3′,0.9,Accept,Experimental Usage,YAP,Plasmid,pLKO.1-puro,,,,Puromycin,,5′-GCCACCAAGCTAGATAAAGAA-3′
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Scramble (TRC1/1.5; SHC002)—5′-CAACAAGATGAAGAGCACCAA-3′,0.9,Accept,Experimental Usage,Scramble,Plasmid,pLKO.1-puro,,,,Puromycin,,5′-CAACAAGATGAAGAGCACCAA-3′
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,Merlin knockdown U251-S cells were treated with siRNA SMARTpool (Thermo Scientific) directed to Merlin,0.85,Accept,Experimental Usage,Merlin siRNA,Other,,,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,cells were transfected with pXJ40-HA-Merlin and S518A pXJ40- HA-Merlin,0.9,Accept,Experimental Usage,HA-Merlin,Plasmid,pXJ40,,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,cells were transfected with pXJ40-HA-Merlin and S518A pXJ40- HA-Merlin,0.9,Accept,Experimental Usage,S518A HA-Merlin,Plasmid,pXJ40,,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,Cells were treated with IPA-3 (Sigma-Aldrich) a PAK group1 inhibitor (PAK1/2/3),0.8,Accept,Experimental Usage,IPA-3,,,,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,were fractionated using the Q-proteome cell compartment kit (Qiagen) following manufacturer's instructions,0.8,Accept,Experimental Usage,Q-proteome cell compartment kit,,,,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,Co-IP experiments were performed without deviation from Co-IP kit protocol (Thermo Scientific),0.8,Accept,Experimental Usage,Co-IP kit,,,,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Total RNA of cultured cells was extracted using the Rneasy Mini Kit (Qiagen, Germantown, MD)",0.8,Accept,Experimental Usage,Rneasy Mini Kit,,,,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,500ng of RNA were reverse-transcribed using the SuperScript™ III first-strand synthesis system for RT-PCR (Life Technologies),0.8,Accept,Experimental Usage,SuperScript III first-strand synthesis system,,,,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,quantitative real-time PCR (Q-PCR) using Power SYBR Green PCR master mix (Life Technologies),0.8,Accept,Experimental Usage,Power SYBR Green PCR master mix,,,,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,The Vybrant ® MTT cell proliferation assay kit quick protocol (Life Technologies) was employed,0.8,Accept,Experimental Usage,Vybrant MTT cell proliferation assay kit,,,,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,Genetic testing was performed using the customized I2HCP panel in blood or tissue when available.,0.85,Accept,Experimental Usage,I2HCP panel,Other,,,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,"The 25-mer-specific PMOs for four patients with splicing variants, and a pair of PMOs to induce exon skipping of exons 4, 8, and 11 of the NF2 gene were designed",0.9,Accept,Experimental Usage,PMOs,Other,,,Human,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,Endo-Porter (Gene Tools) was used as vehicle to deliver PMOs into cells at 6 μM,0.85,Accept,Experimental Usage,Endo-Porter,Other,,,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,"AClick-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit (Molecular Probes, Invitrogen) was used, according to the manufacturer's protocol, to determine cell proliferation",0.85,Accept,Experimental Usage,Click-iT EdU Alexa Fluor 488,Other,,,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,Cell viability was assessed using RealTime-Glo MT Cell Viability Assay (Promega) following the manufacturer's instructions,0.85,Accept,Experimental Usage,RealTime-Glo MT,Other,,,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,The NF2 gene was cloned using the Gateway Gene Cloning system (Invitrogen) after treatment to induce the exon-skipping to an FLAG Tag Expression Vector,0.9,Accept,Experimental Usage,Gateway Gene Cloning system,Other,,,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,The NF2 gene was cloned using the Gateway Gene Cloning system (Invitrogen) after treatment to induce the exon-skipping to an FLAG Tag Expression Vector,0.9,Accept,Experimental Usage,FLAG Tag,Plasmid,,,,,FLAG,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,"The expression vector was transfected into HeLa cells (Lipofectamine LTX with Plus Reagent, Invitrogen)",0.85,Accept,Experimental Usage,Lipofectamine LTX,Other,,,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,"AdCMVNeuroD1 at 2 × 109 pfu/mL, or AdCMVNeuroD1 at 5 × 109 pfu/mL (ViraQuest, Inc.) were applied to the culture medium",0.9,Accept,Experimental Usage,NeuroD1,Viral,,CMV,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,"Adenovirus (Ad) CMVempty vector (EV) at 5 × 109 pfu/mL, AdCMVNeuroD1 at 2 × 109 pfu/mL",0.85,Accept,Experimental Usage,empty vector,Viral,,CMV,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,EdU was detected in whole ganglion using the Click-It EdU kit per manufacturer's instructions (Life Technologies),0.8,Accept,Experimental Usage,EdU detection,,,,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Edu staining was performed using Click-it EdU Alexa Fluor 633 Image Kit (ThermoFisher C10340),0.85,Accept,Experimental Usage,EdU detection,,,,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Sequence-based reagent Tgfb3-MO Gene Tools, LLC Lissamine-tagged, tgfb3-targeting Morpholino",0.9,Accept,Experimental Usage,Tgfb3,Other,,,,,,,5' TGCATGGTTAATATCTGCACACTAT
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Sequence-based reagent Tgfb1b-MO Gene Tools, LLC Lissamine-tagged, tgfb1b-targeting Morpholino",0.9,Accept,Experimental Usage,Tgfb1b,Other,,,,,,,5' AAGGATAGTGCCACTCACTCATTGT
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,Recombinant DNA reagent pCS2+ tgfb3-EGFP This paper; Figure 3—figure supplement 1B Vector for generating RNA,0.9,Accept,Development,tgfb3-EGFP,Plasmid,pCS2+,,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Recombinant DNA reagent pCS2-nCas9n-nanos3'UTR Addgene, Plasmid #62542",0.9,Accept,Experimental Usage,nCas9n-nanos3'UTR,Plasmid,pCS2,,,,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,"Cell viability was assessed using the CellTiter-Glo Luminescent Cell Viability Assay (Cat# G755B/G756B; Promega, Madison, WI, USA)",0.8,Accept,Experimental Usage,CellTiter-Glo,,,,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,Total RNA was isolated using the Direct-zol RNA Miniprep Kit (Zymo).,0.8,Accept,Experimental Usage,RNA isolation kit,,,,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,Libraries were prepared using the TruSeq Stranded Total RNA Library Prep Kit (Illumina),0.8,Accept,Experimental Usage,RNA library preparation kit,,,,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"[3H]-SCH23390, [3H]-raclopride, [3H]-Win 35428 (PerkinElmer Life and Analytical Sciences; Shelton, CT)",0.85,Accept,Experimental Usage,SCH23390,,,,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"[3H]-SCH23390, [3H]-raclopride, [3H]-Win 35428 (PerkinElmer Life and Analytical Sciences; Shelton, CT)",0.85,Accept,Experimental Usage,raclopride,,,,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"[3H]-SCH23390, [3H]-raclopride, [3H]-Win 35428 (PerkinElmer Life and Analytical Sciences; Shelton, CT)",0.85,Accept,Experimental Usage,Win 35428,,,,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"[3H]-WC-10, and [3H]-a-Dihydrotetrabenazine ([3H]-DTBZ; American Radiolabeled Chemicals; St. Louis, MO)",0.85,Accept,Experimental Usage,WC-10,,,,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"[3H]-a-Dihydrotetrabenazine ([3H]-DTBZ; American Radiolabeled Chemicals; St. Louis, MO)",0.85,Accept,Experimental Usage,DTBZ,,,,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,Mice were injected with ~200μCi of [11C]-raclopride (~2500 Ci/mmol specific activity) via the tail vein,0.85,Accept,Experimental Usage,raclopride,,,,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,hybridization with a Cy3-labeled peptide nucleic acid (PNA) probe complementary to the mammalian telomere repeat sequence [(N-terminus to C-terminus) CCCTAACCCTAACCCTAA],0.85,Accept,Experimental Usage,telomere repeat sequence probe,,,,Human,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,an Alexa Fluor-488–labeled PNA probe specific to human centromeric DNA repeats was also included as a control to assess the validity of the hybridization,0.85,Accept,Experimental Usage,centromeric DNA repeats probe,,,,Human,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,"DNA libraries were prepared using Agilent SureSelect-XT reagents (Agilent Technologies, Inc., Santa Clara, CA)",0.8,Accept,Experimental Usage,Agilent SureSelect-XT reagents,Other,,,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,Genomic regions of interest were captured using an Agilent custom-designed bait set covering the full coding regions of 644 cancer associated genes,0.85,Accept,Experimental Usage,644 cancer gene panel,Other,,,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,"Whole-exome capture was performed using either the SeqCap EZ Human Exome Library (Nimblegen, Basel, Switzerland)",0.85,Accept,Experimental Usage,Human Exome,Other,,,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,"Whole-exome capture was performed using either the SeqCap EZ Human Exome Library (Nimblegen, Basel, Switzerland) or TruSeq Exome kit (Illumina, San Diego, CA)",0.85,Accept,Experimental Usage,Human Exome,Other,,,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,"PCR amplicons were cloned into pcDNA3.1 vector (Life Technologies, CA, USA)",0.9,Accept,Experimental Usage,pcDNA3.1,Plasmid,pcDNA3.1,,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,"Cells were pelleted and re-suspended in Minimum Essential Medium (MEM) Alpha (Life Technologies, CA, USA)",0.75,Accept,Experimental Usage,MEM Alpha,Other,,,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,gRNAs targeting zebrafish nf2a/b were validated and cloned in the pU6(x):sgRNA#(x) vectors,0.8,Accept,Experimental Usage,sgRNA,Plasmid,pU6(x),U6,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,All four guides were cloned into the final destination vector pGGDestTol2LC-4sgRNA (nf2a/b-4sgRNA),0.85,Accept,Experimental Usage,nf2a/b-4sgRNA,Plasmid,pGGDestTol2LC,,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,"After administration of 179 MBq [68Ga]Ga-LNTH-1363S, (FAP-directed radiotracer; mass dose, 90 ug)",0.85,Accept,Experimental Usage,LNTH-1363S,Other,,,,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,using the following pig TaqMan primers ( DUSP6 -Ss06941845_m1;  FOS  -Ss03390402_m1; normalized to the average of pig housekeeping genes,0.9,Accept,Experimental Usage,DUSP6,,,,Pig,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,using the following pig TaqMan primers ( DUSP6 -Ss06941845_m1;  FOS  -Ss03390402_m1; normalized to the average of pig housekeeping genes,0.9,Accept,Experimental Usage,FOS,,,,Pig,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,The plasmids pCW57.1 (Addgene plasmid 41393),0.9,Accept,Experimental Usage,pCW57.1,Plasmid,pCW57.1,,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,pDONR223 KRAS WT (Addgene plasmid 81751),0.9,Accept,Experimental Usage,KRAS WT,Plasmid,pDONR223,,Human,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,pDONR223 KRAS G12D (Addgene plasmid 81651),0.9,Accept,Experimental Usage,KRAS G12D,Plasmid,pDONR223,,Human,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,Ras-GTP assays were performed with the Active RAS Pull-Down Kit (Thermo Fisher),0.85,Accept,Experimental Usage,Active RAS Pull-Down Kit,,,,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,"containing either Ad5-CMV-GFP or Ad5-CMV-cre (Vector development lab, Baylor College of Medicine)",0.85,Accept,Experimental Usage,GFP,Viral,Ad5,CMV,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,"containing either Ad5-CMV-GFP or Ad5-CMV-cre (Vector development lab, Baylor College of Medicine)",0.85,Accept,Experimental Usage,Cre,Viral,Ad5,CMV,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Trametinib (a MEK inhibitor) and BMP2 released locally at the fracture site,0.8,Accept,Experimental Usage,Trametinib,,,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,MM cells in log growth phase were treated with vehicle control or c-Met inhibitors SU-11274 (5 μM),0.85,Accept,Experimental Usage,SU-11274,,,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,or SGX2943 (5 μM Calbiochem) for 24 h before harvesting for protein extraction,0.85,Accept,Experimental Usage,SGX2943,,,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Cells were nucleofected with siRNA against Tp53 or miR34a (Dharmacon),0.9,Accept,Experimental Usage,Tp53,Other,,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Cells were nucleofected with siRNA against Tp53 or miR34a (Dharmacon),0.9,Accept,Experimental Usage,miR34a,Other,,,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,White blood cells were isolated using ficoll (Sigma-Aldrich) from fresh whole blood,0.8,Accept,Experimental Usage,ficoll,Other,,,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,complete medium consisting of RPMI 1640 supplemented with 12.5% FCS,0.75,Accept,Experimental Usage,RPMI 1640,Other,,,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,Lymphocyte growth was stimulated with 50 µl/ml PHA (Gibco),0.8,Accept,Experimental Usage,PHA,Other,,,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,stimulated with 50 µl/ml PHA (Gibco) and 10 units/ml of IL-2 (Roche),0.8,Accept,Experimental Usage,IL-2,Other,,,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,one part was treated with 200 µg/ml of puromycin (Sigma-Aldrich) as an inhibitor of nonsense mediated RNA decay,0.8,Accept,Experimental Usage,puromycin,Other,,,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,Total RNA was purified and DNAseI treated using RNeasy Plus micro columns (Qiagen),0.8,Accept,Experimental Usage,RNeasy Plus micro columns,Other,,,,,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,ES was performed by standard procedures using the IGT-T192V1 Plus panel (Integrated DNA Technologies) to capture selected targets.,0.8,Accept,Experimental Usage,IGT-T192V1 Plus panel,Other,,,,,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,"A total of 50 ng of genomic DNA purified from peripheral blood (Qiagen DNA Blood Midi/Mini kit, Qiagen GmbH)",0.75,Accept,Experimental Usage,Qiagen DNA Blood Midi/Mini kit,Other,,,,,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,"The modified fragments were then ligated with barcoded adapters (Fast DNA Library Prep Set CW3045M, CWBIO Inc).",0.75,Accept,Experimental Usage,Fast DNA Library Prep Set CW3045M,Other,,,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,The cDNA fragments were cloned in pMAL-c2X vector (New England Biolabs) for the expression of recombinant proteins as MBP fusions,0.8,Accept,Experimental Usage,MBP fusion,Plasmid,pMAL-c2X,,Human,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,Bacterially expressed His-p55 was immobilized on the CM5 sensor chip,0.75,Accept,Experimental Usage,His-p55,Other,,,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,genomic DNA was isolated and subjected to whole genome amplification according to manufacturers instructions using the REPLI-g FFPE kit (Qiagen),0.85,Accept,Experimental Usage,REPLI-g FFPE,,,,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Detection was performed using the Bond Polymer Refine Kit (DS9800, Leica Biosystems)",0.8,Accept,Experimental Usage,Bond Polymer Refine Kit,Other,,,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"cells first underwent fixation and permeabilization using the eBioscience ™ FOXP3/Transcription Factor Fixation/Permeabilization kit (Thermo Fisher Scientific, #00552100,)",0.8,Accept,Experimental Usage,FOXP3/Transcription Factor Fixation/Permeabilization kit,Other,,,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"depletion was performed with KAPA RiboErase HMR (Roche, #07962274001)",0.8,Accept,Experimental Usage,KAPA RiboErase HMR,Other,,,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"samples were prepared with TruSeq ® Stranded Total RNA Library Prep Gold kit (Illumina, #20020599)",0.8,Accept,Experimental Usage,TruSeq Stranded Total RNA Library Prep Gold kit,Other,,,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,"The first vectors used to generate iPSCs were gamma retroviruses, specifically murine leukemia retroviruses, chosen for their favorable long-term transgene expression",0.8,Accept,Experimental Usage,reprogramming factors,Viral,,,Human,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,"The first vectors used to generate iPSCs were gamma retroviruses, specifically murine leukemia retroviruses, chosen for their favorable long-term transgene expression",0.8,Accept,Experimental Usage,reprogramming factors,Viral,,,Human,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,"Lentiviral vectors, a retroviral subclass, can transduce both non-dividing and rapidly-dividing cells with efficiencies comparable to other retroviruses",0.8,Accept,Experimental Usage,reprogramming factors,Viral,,,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,excisable lentiviral vectors have been developed using Cre/loxP technology,0.9,Accept,Experimental Usage,Cre,Other,,,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,Adenoviral vectors are considered a non-integrative option for reprogramming factor delivery,0.8,Accept,Experimental Usage,reprogramming factors,Viral,,,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,Sendai viral vectors are another non-integrative reprogramming alternative,0.8,Accept,Experimental Usage,reprogramming factors,Viral,,,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,"human fibroblasts have been successfully reprogrammed after a single transfection with oriP/EBNA1 (Epstein-Barr nuclear antigen-1)-based episomal vectors expressing OCT4, SOX2, MYC, KLF4, NANOG, LIN28",0.9,Accept,Experimental Usage,"OCT4, SOX2, MYC, KLF4, NANOG, LIN28",Plasmid,oriP/EBNA1,,Human,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,a virus expressing the full-length NF1 GTPase-activating related domain (NF1 GRD) and pac (MSCV-NF1 GRD-pac),0.9,Accept,Experimental Usage,NF1 GRD,Viral,MSCV,,,,Puromycin,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,a virus expressing a GAP-inactive mutant of the NF1 GRD that harbors a known human mutation in the arginine finger loop (R1276P) and pac (MSCV-1276P NF1 GRD-pac),0.9,Accept,Experimental Usage,1276P NF1 GRD,Viral,MSCV,,,,Puromycin,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,a virus expressing the selectable marker gene alone (MSCV-pac),0.85,Accept,Experimental Usage,pac,Viral,MSCV,,,,Puromycin,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"c-abl siRNA oligonucleotides (Cat. no. sc-29844) were purchased from Santa Cruz Biotechnology, Inc.",0.9,Accept,Experimental Usage,c-abl siRNA,Other,,,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,Scrambled oligonucleotides (Cat. no. sc-36869) or vehicle only was used as controls,0.85,Accept,Experimental Usage,Scrambled siRNA,Other,,,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"p21 ras activation was subsequently determined using a p21 ras activation pulldown assay kit (Upstate Biotechnology, Lake Placid, NY, USA)",0.8,Accept,Experimental Usage,p21 ras activation assay,Other,,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"cells were transfected with the control lentivirus (LV-vector), NF-1 sgRNA-CAS9 lentivirus (LV-NF-1), Rictor sgRNA-CAS9 lentivirus (LV-Rictor)",0.9,Accept,Experimental Usage,NF-1,Viral,lentiviral,,,,GFP,,5′- TCCGAAGTTCGGCTGCATGT -3′
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"cells were transfected with the control lentivirus (LV-vector), NF-1 sgRNA-CAS9 lentivirus (LV-NF-1), Rictor sgRNA-CAS9 lentivirus (LV-Rictor)",0.9,Accept,Experimental Usage,Rictor,Viral,lentiviral,,,,GFP,,5′- ATAGCGCAGCGCTCGCAACC -3′
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"The TUNEL assay was conducted by using the TUNEL kit (Roche, Reinach, Switzerland)",0.8,Accept,Experimental Usage,TUNEL,Other,,,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,"Pharmacologic inhibitor experiments used 104 cells per well (NSC23766, 10 µM; AG825, 10 µM; Sigma, St. Louis MO)",0.8,Accept,Experimental Usage,NSC23766,,,,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,"Pharmacologic inhibitor experiments used 104 cells per well (NSC23766, 10 µM; AG825, 10 µM; Sigma, St. Louis MO)",0.8,Accept,Experimental Usage,AG825,,,,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Murine stem cell virus (MSCV) infection was employed to express human WT or mutant (L64P patient mutation) merlin,0.85,Accept,Experimental Usage,MSCV,Viral,,,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,dominant-negative Rac1 (Rac1 N17) as previously described [15],0.85,Accept,Experimental Usage,Rac1 N17,,,,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,PLKO virus was used as an empty vector control,0.8,Accept,Experimental Usage,PLKO,Viral,,,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,"Active Rac1 (Rac1-GTP) was determined by PAK1-PBD affinity chromatography (Rac1 activation Assay Kit, Millipore, Bedford MA)",0.8,Accept,Experimental Usage,Rac1 activation Assay Kit,,,,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"MEK inhibitor (MEKi, PD0325901, Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO at a concentration of 25 mg/ml",0.85,Accept,Experimental Usage,PD0325901,Other,,,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,"Human MCL-1-glutathione-S-transferase (GST) and BCL-XL-GST fusion proteins were cloned into the pGEX 4T-1 expression plasmid (available from Addgene, Watertown, MA, USA)",0.85,Accept,Experimental Usage,pGEX 4T-1,Plasmid,pGEX,,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,"MCF7 cells (1 × 10 6 ) were transfected with 1 µg of a 12:1 DNA ratio of the pCMV-T7-(FZ) SpCas9-BPNLS(SV40)-3xFLAG-P2A-Puro-R plasmid (modified from RTW3027, Addgene #139987)",0.9,Accept,Experimental Usage,SpCas9,Plasmid,,CMV,,,Puromycin,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,Transcript level of the following genes were analyzed using an Illumina custom panel,0.85,Accept,Experimental Usage,Custom gene panel,Other,,,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,"we electroporated the afferent fibers to the calyx of Held with Alexa Fluor 594-labeled dextrans (10,000 MW; Invitrogen)",0.9,Accept,Experimental Usage,Alexa Fluor 594-labeled dextrans,,,,Unknown,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,Probes used were a centromeric-enumerating probe Vysis CEP 8 (D8Z2) SpectrumGreen combined with locus-specific probe,0.9,Accept,Experimental Usage,CEP 8 (D8Z2),Other,,,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,combined with locus-specific probe Vysis LSI MYC SpectrumOrange (Abbott Molecular),0.9,Accept,Experimental Usage,LSI MYC,Other,,,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,"The gDNA was purified starting from formalin-fixed paraffin-embedded (FFPE) samples obtained at surgical resection, using the Magcore DNA FFPE One-Step Kit (Code 405).",0.85,Accept,Experimental Usage,DNA extraction reagent,Other,,,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,Fragmented gDNAs were tested for size distribution and concentration using an Agilent Tapestation 4200 and Qubit dsDNA High Sensitivity kit.,0.85,Accept,Experimental Usage,DNA quantification reagent,Other,,,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,"The NGS library was executed using the Agilent Sure Select XT HS2 all exon v8 kit (Agilent, Santa Clara, CA, USA), following the manufacturer's instructions.",0.9,Accept,Experimental Usage,exome capture reagent,Other,,,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,stably transfected with plasmid pSG5 vector and encoding PSME3 cDNA harbor PA28у cDNA under a constitutive SV40 promotor,0.85,Accept,Experimental Usage,PSME3,Plasmid,pSG5,SV40,,,G418,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,adenovirus containing Cas9 and sgRNAs targeting Nf1+Cdkn2a were produced,0.9,Accept,Experimental Usage,Cas9 and sgRNAs targeting Nf1+Cdkn2a,Viral,,,Mouse,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"Small-molecule Ref-1 inhibitors APX3330, APX2009 and APX2014 (Apexian Pharmaceuticals, Indianapolis, IN, USA)",0.85,Accept,Experimental Usage,APX3330,,,,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"Small-molecule Ref-1 inhibitors APX3330, APX2009 and APX2014 (Apexian Pharmaceuticals, Indianapolis, IN, USA)",0.85,Accept,Experimental Usage,APX2009,,,,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"Small-molecule Ref-1 inhibitors APX3330, APX2009 and APX2014 (Apexian Pharmaceuticals, Indianapolis, IN, USA)",0.85,Accept,Experimental Usage,APX2014,,,,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"STAT3 inhibitor Napabucasin (SelleckChem, Houston, TX, USA) was dissolved in 100% DMSO",0.8,Accept,Experimental Usage,Napabucasin,,,,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,JAK1/2 kinase inhibitor Ruxolitinib (SelleckChem) was dissolved in 100% DMSO,0.8,Accept,Experimental Usage,Ruxolitinib,,,,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,MPNST cells were transfected with Ref-1 #1 siRNA (sequence previously reported),0.9,Accept,Experimental Usage,Ref-1,Other,,,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"LifeTech validated Ref-1 siRNA (s1447, Santa Cruz, Dallas, TX, USA)",0.9,Accept,Experimental Usage,Ref-1,Other,,,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"validated STAT3 siRNAs (sc-44275, sc-29493) and scrambled control",0.9,Accept,Experimental Usage,STAT3,Other,,,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,"All cultures were routinely tested for mycoplasma contamination (LookOut Mycoplasma PCR detection kit, Sigma-Aldrich, St. Louis, MO, USA)",0.85,Accept,Experimental Usage,Mycoplasma detection primers,,,,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,"the human Hsp90β sequence was optimized and cloned into a pBad/Myc-Hisx6 vector (Invitrogen, Thermo Fisher Scientific)",0.9,Accept,Experimental Usage,Hsp90β,Plasmid,pBad,,,,Myc-Hisx6,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,Recombinant wild-type Hsp90β was purified from the bacterial culture using a Ni-NTA purification system (Invitrogen),0.8,Accept,Experimental Usage,Ni-NTA resin,,,,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,"4 μL of the lipophilic cell permeation agent Chariot (Active Motif, Carlsbad, CA, USA) in 100 μL ddH2O",0.85,Accept,Experimental Usage,Chariot protein delivery reagent,,,,,,,,
